Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

FEV1 funnel plot.Funnel plot asymmetry of studies reporting change in FEV1 in the studies assembled. The distribution of effect estimates could actually be attributable to more than one common effect, rather than underreporting of negative data for this outcome.
Figuras y tablas -
Figure 1

FEV1 funnel plot.

Funnel plot asymmetry of studies reporting change in FEV1 in the studies assembled. The distribution of effect estimates could actually be attributable to more than one common effect, rather than underreporting of negative data for this outcome.

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP100 withdrawals.In order to prevent 1 trial withdrawal due to clinical deterioration of asthma, 4 people would need to be treated with FP at 100mcg/d.
Figuras y tablas -
Figure 2

FP100 withdrawals.

In order to prevent 1 trial withdrawal due to clinical deterioration of asthma, 4 people would need to be treated with FP at 100mcg/d.

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP200 withdrawals.NNT to show that three people need treatment with FP at 200mcg/d to prevent 1 withdrawal due to deterioration of asthma
Figuras y tablas -
Figure 3

FP200 withdrawals.

NNT to show that three people need treatment with FP at 200mcg/d to prevent 1 withdrawal due to deterioration of asthma

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP500 wthdrawals.NNT to show that 3 people need to be treated with FP at 500mcg/d to prevent one trial withdrawal due to deteriorating asthma
Figuras y tablas -
Figure 4

FP500 wthdrawals.

NNT to show that 3 people need to be treated with FP at 500mcg/d to prevent one trial withdrawal due to deteriorating asthma

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP1000 withdrawals.NNT to show that 3 people need treatment with FP at 1000mcg/d to prevent one withdrawal due to deterioration of asthma.
Figuras y tablas -
Figure 5

FP1000 withdrawals.

NNT to show that 3 people need treatment with FP at 1000mcg/d to prevent one withdrawal due to deterioration of asthma.

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP500 pharyngitis.Graphic to demonstrate that for every 100 people treated with FP at a dose of 500 mcg, around 73 would need to be treated in order for one person to develop sore throat.
Figuras y tablas -
Figure 6

FP500 pharyngitis.

Graphic to demonstrate that for every 100 people treated with FP at a dose of 500 mcg, around 73 would need to be treated in order for one person to develop sore throat.

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP1000 pharyngitis.
Figuras y tablas -
Figure 7

FP1000 pharyngitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP500 hoarse/dysphon.Graphic to demonstrate that 148 people need to be treated with FP500 in order for one to develop hoarseness/dysphonia
Figuras y tablas -
Figure 8

FP500 hoarse/dysphon.

Graphic to demonstrate that 148 people need to be treated with FP500 in order for one to develop hoarseness/dysphonia

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP1000 hoarse/dyspho.Graphic to demonstrate that 30 people need to be treated with FP1000 mcg/d in order for one to develop hoarseness/dysphonia
Figuras y tablas -
Figure 9

FP1000 hoarse/dyspho.

Graphic to demonstrate that 30 people need to be treated with FP1000 mcg/d in order for one to develop hoarseness/dysphonia

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP500 candidiasis.Visual graphic to demonstrate that 76 people would need to be treated with 500mcg/d of FP in order for one person to develop oral candidiasis
Figuras y tablas -
Figure 10

FP500 candidiasis.

Visual graphic to demonstrate that 76 people would need to be treated with 500mcg/d of FP in order for one person to develop oral candidiasis

Ir a la figura de la revisiónAbrir en una pestaña nueva

FP1000 candidiasis.Graphic to demonstrate that 29 people need to be treated with FP1000mcg/d in order for one person to develop oral candidiasis
Figuras y tablas -
Figure 11

FP1000 candidiasis.

Graphic to demonstrate that 29 people need to be treated with FP1000mcg/d in order for one person to develop oral candidiasis

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 1.1

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 2 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 1.2

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 2 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 3 FEV1 ‐ Litres (absolute values).
Figuras y tablas -
Analysis 1.3

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 3 FEV1 ‐ Litres (absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 4 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 1.4

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 4 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 5 Change in am PEF (predicted).
Figuras y tablas -
Analysis 1.5

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 5 Change in am PEF (predicted).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 6 Change in evening PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 1.6

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 6 Change in evening PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 7 Change in evening PEFR compared to baseline.
Figuras y tablas -
Analysis 1.7

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 7 Change in evening PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 8 Change in evening PEF (predicted).
Figuras y tablas -
Analysis 1.8

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 8 Change in evening PEF (predicted).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 9 Peak flow ‐ L/min (absolute values).
Figuras y tablas -
Analysis 1.9

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 9 Peak flow ‐ L/min (absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 10 Change in clinic PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 1.10

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 10 Change in clinic PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 11 Change in FVC compared to baseline (litres).
Figuras y tablas -
Analysis 1.11

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 11 Change in FVC compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 12 Change in FEF25‐75 compared to baseline (L/second).
Figuras y tablas -
Analysis 1.12

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 12 Change in FEF25‐75 compared to baseline (L/second).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 13 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 1.13

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 13 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 14 Symptoms ‐ absolute scores.
Figuras y tablas -
Analysis 1.14

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 14 Symptoms ‐ absolute scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 15 Change in night‐time wakening score.
Figuras y tablas -
Analysis 1.15

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 15 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 16 Nighttime awakenings/night.
Figuras y tablas -
Analysis 1.16

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 16 Nighttime awakenings/night.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 17 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 1.17

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 17 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 18 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 1.18

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 18 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 19 Rescue medication usage ‐ puffs/d (absolute scores).
Figuras y tablas -
Analysis 1.19

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 19 Rescue medication usage ‐ puffs/d (absolute scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 20 HRQOL: AQLQ.
Figuras y tablas -
Analysis 1.20

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 20 HRQOL: AQLQ.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 21 HRQOL: Functional Status IIR questionaire (short version).
Figuras y tablas -
Analysis 1.21

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 21 HRQOL: Functional Status IIR questionaire (short version).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 22 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, burden dimension.
Figuras y tablas -
Analysis 1.22

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 22 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, burden dimension.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 23 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, subjective norms dimension.
Figuras y tablas -
Analysis 1.23

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 23 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, subjective norms dimension.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 24 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, social dimension.
Figuras y tablas -
Analysis 1.24

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 24 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, social dimension.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 25 HRQOL: Sleep Scale Children questionnaire.
Figuras y tablas -
Analysis 1.25

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 25 HRQOL: Sleep Scale Children questionnaire.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 26 Physician‐rated efficacy: effective or very effective.
Figuras y tablas -
Analysis 1.26

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 26 Physician‐rated efficacy: effective or very effective.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 27 Withdrawal due to clinical asthma exacerbation (No. of patients).
Figuras y tablas -
Analysis 1.27

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 27 Withdrawal due to clinical asthma exacerbation (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 28 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 1.28

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 28 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 29 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 1.29

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 29 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 30 Morning plasma cortisol (mcg/dL).
Figuras y tablas -
Analysis 1.30

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 30 Morning plasma cortisol (mcg/dL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 31 Total urinary free cortisol excretion (mcg/24 hours).
Figuras y tablas -
Analysis 1.31

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 31 Total urinary free cortisol excretion (mcg/24 hours).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 32 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 1.32

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 32 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 33 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 1.33

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 33 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 34 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 1.34

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 34 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 35 Headaches.
Figuras y tablas -
Analysis 1.35

Comparison 1 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages), Outcome 35 Headaches.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 2.1

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 2 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 2.2

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 2 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 3 Change in evening PEFR compared to baseline.
Figuras y tablas -
Analysis 2.3

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 3 Change in evening PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 4 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 2.4

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 4 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 5 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 2.5

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 5 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 6 Change in night‐time wakening score.
Figuras y tablas -
Analysis 2.6

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 6 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 7 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 2.7

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 7 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 8 Physician‐rated efficacy: effective or very effective.
Figuras y tablas -
Analysis 2.8

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 8 Physician‐rated efficacy: effective or very effective.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 9 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 2.9

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 9 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 10 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 2.10

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 10 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 11 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 2.11

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 11 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 12 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 2.12

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 12 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 13 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 2.13

Comparison 2 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations), Outcome 13 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 3.1

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 2 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 3.2

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 2 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 3 Change in evening PEFR compared to baseline.
Figuras y tablas -
Analysis 3.3

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 3 Change in evening PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 4 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 3.4

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 4 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 5 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 3.5

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 5 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 6 Change in night‐time wakening score.
Figuras y tablas -
Analysis 3.6

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 6 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 7 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 3.7

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 7 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 8 Physician‐rated efficacy: effective or very effective.
Figuras y tablas -
Analysis 3.8

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 8 Physician‐rated efficacy: effective or very effective.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 9 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 3.9

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 9 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 10 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 3.10

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 10 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 11 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 3.11

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 11 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 12 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 3.12

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 12 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 13 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 3.13

Comparison 3 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices), Outcome 13 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 4.1

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 2 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 4.2

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 2 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 3 Change in evening PEFR compared to baseline.
Figuras y tablas -
Analysis 4.3

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 3 Change in evening PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 7 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 4.7

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 7 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 8 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 4.8

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 8 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 9 Change in night‐time wakening score.
Figuras y tablas -
Analysis 4.9

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 9 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 10 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 4.10

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 10 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 16 Physician‐rated efficacy: effective or very effective.
Figuras y tablas -
Analysis 4.16

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 16 Physician‐rated efficacy: effective or very effective.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 18 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 4.18

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 18 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 21 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 4.21

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 21 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 22 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 4.22

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 22 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 23 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 4.23

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 23 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 24 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 4.24

Comparison 4 FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity), Outcome 24 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 5.1

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 2 Change in FEV1 compared to baseline (imputed estimates).
Figuras y tablas -
Analysis 5.2

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 2 Change in FEV1 compared to baseline (imputed estimates).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 3 Change in FEV1 (% predicted).
Figuras y tablas -
Analysis 5.3

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 3 Change in FEV1 (% predicted).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 4 Change in FEV1 (%).
Figuras y tablas -
Analysis 5.4

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 4 Change in FEV1 (%).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 5 FEV1 (% predicted ‐ absolute values).
Figuras y tablas -
Analysis 5.5

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 5 FEV1 (% predicted ‐ absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 6 FEV1 (absolute values).
Figuras y tablas -
Analysis 5.6

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 6 FEV1 (absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 7 Change in morning PEFR compared with baseline.
Figuras y tablas -
Analysis 5.7

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 7 Change in morning PEFR compared with baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 8 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 5.8

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 8 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 9 Mean change in am PEF (% predicted).
Figuras y tablas -
Analysis 5.9

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 9 Mean change in am PEF (% predicted).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 10 Change in evening PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 5.10

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 10 Change in evening PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 11 Change in evening PEFR compared to baseline.
Figuras y tablas -
Analysis 5.11

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 11 Change in evening PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 12 Change in clinic PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 5.12

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 12 Change in clinic PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 13 Peak flow L/min (absolute values).
Figuras y tablas -
Analysis 5.13

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 13 Peak flow L/min (absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 14 Change in FVC compared to baseline (litres).
Figuras y tablas -
Analysis 5.14

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 14 Change in FVC compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 15 Change in FEF25‐75 compared to baseline (L/second).
Figuras y tablas -
Analysis 5.15

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 15 Change in FEF25‐75 compared to baseline (L/second).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 16 Histamine BHR (log base 2 PC20 FEV1 mg/ml).
Figuras y tablas -
Analysis 5.16

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 16 Histamine BHR (log base 2 PC20 FEV1 mg/ml).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 17 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 5.17

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 17 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 18 Change in night‐time wakening score.
Figuras y tablas -
Analysis 5.18

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 18 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 19 Change in symptom free days.
Figuras y tablas -
Analysis 5.19

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 19 Change in symptom free days.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 20 Change from baseline in symptom free days (%).
Figuras y tablas -
Analysis 5.20

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 20 Change from baseline in symptom free days (%).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 21 Percentage nights without awakening ‐ change from baseline.
Figuras y tablas -
Analysis 5.21

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 21 Percentage nights without awakening ‐ change from baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 22 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 5.22

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 22 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 23 Change from baseline in nighttime awakenings/night.
Figuras y tablas -
Analysis 5.23

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 23 Change from baseline in nighttime awakenings/night.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 24 Change in nocturnal awakenings (unspecified time).
Figuras y tablas -
Analysis 5.24

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 24 Change in nocturnal awakenings (unspecified time).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 25 Symptoms (absolute values).
Figuras y tablas -
Analysis 5.25

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 25 Symptoms (absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 26 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 5.26

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 26 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 27 Change in daily use of beta2 agonist compared to baseline (puffs/d ‐ imputed estimates).
Figuras y tablas -
Analysis 5.27

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 27 Change in daily use of beta2 agonist compared to baseline (puffs/d ‐ imputed estimates).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 28 Change from baseline in rescue medication free days (%).
Figuras y tablas -
Analysis 5.28

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 28 Change from baseline in rescue medication free days (%).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 29 Rescue medication (absolute scores).
Figuras y tablas -
Analysis 5.29

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 29 Rescue medication (absolute scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 30 HRQOL: AQLQ (absolute socres).
Figuras y tablas -
Analysis 5.30

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 30 HRQOL: AQLQ (absolute socres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 31 HRQOL: Functional Status IIR questionaire (short version).
Figuras y tablas -
Analysis 5.31

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 31 HRQOL: Functional Status IIR questionaire (short version).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 32 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, burden dimension.
Figuras y tablas -
Analysis 5.32

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 32 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, burden dimension.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 33 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, subjective norms dimension.
Figuras y tablas -
Analysis 5.33

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 33 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, subjective norms dimension.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 34 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, social dimension.
Figuras y tablas -
Analysis 5.34

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 34 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, social dimension.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 35 HRQOL: Sleep Scale Children questionnaire.
Figuras y tablas -
Analysis 5.35

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 35 HRQOL: Sleep Scale Children questionnaire.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 36 Physician‐rated efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 5.36

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 36 Physician‐rated efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 37 Exacerbations requiring OCS treatment.
Figuras y tablas -
Analysis 5.37

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 37 Exacerbations requiring OCS treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 38 Withdrawal due to clinical asthma exacerbation (No. of patients).
Figuras y tablas -
Analysis 5.38

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 38 Withdrawal due to clinical asthma exacerbation (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 39 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 5.39

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 39 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 40 Withdrawals (any reason).
Figuras y tablas -
Analysis 5.40

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 40 Withdrawals (any reason).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 41 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 5.41

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 41 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 42 Adverse events (any).
Figuras y tablas -
Analysis 5.42

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 42 Adverse events (any).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 43 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 5.43

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 43 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 44 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 5.44

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 44 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 45 Headaches.
Figuras y tablas -
Analysis 5.45

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 45 Headaches.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 46 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 5.46

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 46 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 47 Upper respiratory tract infection.
Figuras y tablas -
Analysis 5.47

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 47 Upper respiratory tract infection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 48 Sinusitis.
Figuras y tablas -
Analysis 5.48

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 48 Sinusitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 49 Total urinary free cortisol excretion (mcg/24 hours).
Figuras y tablas -
Analysis 5.49

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 49 Total urinary free cortisol excretion (mcg/24 hours).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 50 AUC serum cortisol (ng*h/mL).
Figuras y tablas -
Analysis 5.50

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 50 AUC serum cortisol (ng*h/mL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 51 Morning plasma cortisol (mcg/dL).
Figuras y tablas -
Analysis 5.51

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 51 Morning plasma cortisol (mcg/dL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 52 Change in morning plasma cortisol compared to baseline (mcg/dL).
Figuras y tablas -
Analysis 5.52

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 52 Change in morning plasma cortisol compared to baseline (mcg/dL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 53 Change in peak plasma cortisol expression (mcg/dL).
Figuras y tablas -
Analysis 5.53

Comparison 5 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages), Outcome 53 Change in peak plasma cortisol expression (mcg/dL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 6.1

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 2 Change in FEV1 (% predicted).
Figuras y tablas -
Analysis 6.2

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 2 Change in FEV1 (% predicted).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 3 Change in morning PEFR compared with baseline.
Figuras y tablas -
Analysis 6.3

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 3 Change in morning PEFR compared with baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 4 Change in evening PEFR compared to baseline.
Figuras y tablas -
Analysis 6.4

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 4 Change in evening PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 5 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 6.5

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 5 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 6 HRQOL: AQLQ.
Figuras y tablas -
Analysis 6.6

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 6 HRQOL: AQLQ.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 7 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 6.7

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 7 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 8 Change from baseline in symptom free days (%).
Figuras y tablas -
Analysis 6.8

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 8 Change from baseline in symptom free days (%).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 9 Change in night‐time wakening score.
Figuras y tablas -
Analysis 6.9

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 9 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 10 Change from baseline in nighttime awakenings/night.
Figuras y tablas -
Analysis 6.10

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 10 Change from baseline in nighttime awakenings/night.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 11 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 6.11

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 11 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 12 Physician‐rated efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 6.12

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 12 Physician‐rated efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 13 Withdrawal due to clinical asthma exacerbation (No. of patients).
Figuras y tablas -
Analysis 6.13

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 13 Withdrawal due to clinical asthma exacerbation (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 14 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 6.14

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 14 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 15 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 6.15

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 15 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 16 Withdrawals (any reason).
Figuras y tablas -
Analysis 6.16

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 16 Withdrawals (any reason).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 17 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 6.17

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 17 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 18 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 6.18

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 18 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 19 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 6.19

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 19 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 20 Headaches.
Figuras y tablas -
Analysis 6.20

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 20 Headaches.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 21 Sinusitis.
Figuras y tablas -
Analysis 6.21

Comparison 6 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations), Outcome 21 Sinusitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 7.1

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 2 Change in FEV1 (% predicted).
Figuras y tablas -
Analysis 7.2

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 2 Change in FEV1 (% predicted).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 3 Change in morning PEFR compared with baseline.
Figuras y tablas -
Analysis 7.3

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 3 Change in morning PEFR compared with baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 4 Change in evening PEFR compared to baseline.
Figuras y tablas -
Analysis 7.4

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 4 Change in evening PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 5 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 7.5

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 5 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 6 Change from baseline in symptom free days (%).
Figuras y tablas -
Analysis 7.6

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 6 Change from baseline in symptom free days (%).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 7 Change from baseline in nighttime awakenings/night.
Figuras y tablas -
Analysis 7.7

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 7 Change from baseline in nighttime awakenings/night.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 8 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 7.8

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 8 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 9 Change in night‐time wakening score.
Figuras y tablas -
Analysis 7.9

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 9 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 10 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 7.10

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 10 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 11 HRQOL: AQLQ.
Figuras y tablas -
Analysis 7.11

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 11 HRQOL: AQLQ.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 12 Physician‐rated efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 7.12

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 12 Physician‐rated efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 13 Withdrawal due to clinical asthma exacerbation (No. of patients).
Figuras y tablas -
Analysis 7.13

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 13 Withdrawal due to clinical asthma exacerbation (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 14 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 7.14

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 14 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 15 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 7.15

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 15 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 16 Withdrawals (any reason).
Figuras y tablas -
Analysis 7.16

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 16 Withdrawals (any reason).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 17 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 7.17

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 17 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 18 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 7.18

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 18 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 19 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 7.19

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 19 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 20 Headaches.
Figuras y tablas -
Analysis 7.20

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 20 Headaches.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 21 Sinusitis.
Figuras y tablas -
Analysis 7.21

Comparison 7 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices), Outcome 21 Sinusitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 8.1

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 2 Change in FEV1 (% predicted).
Figuras y tablas -
Analysis 8.2

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 2 Change in FEV1 (% predicted).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 3 Change in morning PEFR compared with baseline.
Figuras y tablas -
Analysis 8.3

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 3 Change in morning PEFR compared with baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 4 Change in evening PEFR compared to baseline.
Figuras y tablas -
Analysis 8.4

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 4 Change in evening PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 5 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 8.5

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 5 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 6 Change from baseline in symptom free days (%).
Figuras y tablas -
Analysis 8.6

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 6 Change from baseline in symptom free days (%).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 7 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 8.7

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 7 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 8 Change from baseline in nighttime awakenings/night.
Figuras y tablas -
Analysis 8.8

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 8 Change from baseline in nighttime awakenings/night.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 9 Change in night‐time wakening score.
Figuras y tablas -
Analysis 8.9

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 9 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 10 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 8.10

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 10 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 11 HRQOL: AQLQ.
Figuras y tablas -
Analysis 8.11

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 11 HRQOL: AQLQ.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 12 Physician‐rated efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 8.12

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 12 Physician‐rated efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 13 Withdrawal due to clinical asthma exacerbation (No. of patients).
Figuras y tablas -
Analysis 8.13

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 13 Withdrawal due to clinical asthma exacerbation (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 14 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 8.14

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 14 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 15 Withdrawals due to adverse events.
Figuras y tablas -
Analysis 8.15

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 15 Withdrawals due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 16 Withdrawals (any reason).
Figuras y tablas -
Analysis 8.16

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 16 Withdrawals (any reason).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 17 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 8.17

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 17 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 18 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 8.18

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 18 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 19 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 8.19

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 19 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 20 Headaches.
Figuras y tablas -
Analysis 8.20

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 20 Headaches.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 21 Sinusitis.
Figuras y tablas -
Analysis 8.21

Comparison 8 FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity), Outcome 21 Sinusitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 9.1

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 2 FEV1 (% predicted ‐ absolute scores).
Figuras y tablas -
Analysis 9.2

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 2 FEV1 (% predicted ‐ absolute scores).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 3 Change in morning PEF.
Figuras y tablas -
Analysis 9.3

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 3 Change in morning PEF.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 4 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 9.4

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 4 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 5 Change in am PEF (% predicted).
Figuras y tablas -
Analysis 9.5

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 5 Change in am PEF (% predicted).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 6 Change in evening PEF compared with baseline.
Figuras y tablas -
Analysis 9.6

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 6 Change in evening PEF compared with baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 7 Change in evening PEF compared with baseline (L/min).
Figuras y tablas -
Analysis 9.7

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 7 Change in evening PEF compared with baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 8 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 9.8

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 8 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 9 Change in number night‐time wakenings per week.
Figuras y tablas -
Analysis 9.9

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 9 Change in number night‐time wakenings per week.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 10 Change in number of night‐time awakenings per night.
Figuras y tablas -
Analysis 9.10

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 10 Change in number of night‐time awakenings per night.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 11 Change in % nights with no awakenings.
Figuras y tablas -
Analysis 9.11

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 11 Change in % nights with no awakenings.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 12 Change in night‐time wakening score.
Figuras y tablas -
Analysis 9.12

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 12 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 13 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 9.13

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 13 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 14 Change in percentage of symptom free days compared to baseline.
Figuras y tablas -
Analysis 9.14

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 14 Change in percentage of symptom free days compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 15 Change in percentage of rescue beta2 agonist free days compared to baseline.
Figuras y tablas -
Analysis 9.15

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 15 Change in percentage of rescue beta2 agonist free days compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 16 HRQOL: AQLQ.
Figuras y tablas -
Analysis 9.16

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 16 HRQOL: AQLQ.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 17 Physician rated global efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 9.17

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 17 Physician rated global efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 18 Withdrawal due to clinical asthma exacerbation (No. of patients).
Figuras y tablas -
Analysis 9.18

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 18 Withdrawal due to clinical asthma exacerbation (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 19 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 9.19

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 19 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 20 Withdrawals (total).
Figuras y tablas -
Analysis 9.20

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 20 Withdrawals (total).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 21 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 9.21

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 21 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 22 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 9.22

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 22 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 23 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 9.23

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 23 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 25 No. patients with </=18 mcg/dL poststimulation cortisol.
Figuras y tablas -
Analysis 9.25

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 25 No. patients with </=18 mcg/dL poststimulation cortisol.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 26 Plasma cortisol (AUC).
Figuras y tablas -
Analysis 9.26

Comparison 9 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages), Outcome 26 Plasma cortisol (AUC).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 10.1

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 2 Change in morning PEFR compared to baseline.
Figuras y tablas -
Analysis 10.2

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 2 Change in morning PEFR compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 3 Change in evening PEF compared with baseline (L/min).
Figuras y tablas -
Analysis 10.3

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 3 Change in evening PEF compared with baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 4 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 10.4

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 4 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 5 Change in night‐time wakening score.
Figuras y tablas -
Analysis 10.5

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 5 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 6 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 10.6

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 6 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 9 Physician rated global efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 10.9

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 9 Physician rated global efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 11 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 10.11

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 11 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 12 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 10.12

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 12 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 13 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 10.13

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 13 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 14 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 10.14

Comparison 10 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations), Outcome 14 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 11.1

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 2 Change in morning PEFR compared with baseline.
Figuras y tablas -
Analysis 11.2

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 2 Change in morning PEFR compared with baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 3 Change in evening PEF compared with baseline (L/min).
Figuras y tablas -
Analysis 11.3

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 3 Change in evening PEF compared with baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 4 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 11.4

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 4 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 5 Change in night‐time wakening score.
Figuras y tablas -
Analysis 11.5

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 5 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 6 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 11.6

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 6 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 9 Physician rated global efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 11.9

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 9 Physician rated global efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 10 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 11.10

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 10 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 11 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 11.11

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 11 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 12 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 11.12

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 12 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 13 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 11.13

Comparison 11 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices), Outcome 13 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 1 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 12.1

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 1 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 2 Change in morning PEFR compared with baseline.
Figuras y tablas -
Analysis 12.2

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 2 Change in morning PEFR compared with baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 3 Change in evening PEF compared with baseline (L/min).
Figuras y tablas -
Analysis 12.3

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 3 Change in evening PEF compared with baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 4 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 12.4

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 4 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 5 Change in night‐time wakening score.
Figuras y tablas -
Analysis 12.5

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 5 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 6 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 12.6

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 6 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 7 Physician rated global efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 12.7

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 7 Physician rated global efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 8 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 12.8

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 8 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 9 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 12.9

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 9 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 10 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 12.10

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 10 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 11 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 12.11

Comparison 12 FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity), Outcome 11 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 1 FEV1 (litres).
Figuras y tablas -
Analysis 13.1

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 1 FEV1 (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 2 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 13.2

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 2 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 3 Change in FVC compared to baseline (litres).
Figuras y tablas -
Analysis 13.3

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 3 Change in FVC compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 4 Change in FEF25‐75 compared to baseline (L/second).
Figuras y tablas -
Analysis 13.4

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 4 Change in FEF25‐75 compared to baseline (L/second).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 5 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 13.5

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 5 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 6 Change in evening PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 13.6

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 6 Change in evening PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 7 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 13.7

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 7 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 8 Change in number of night‐time awakenings per week compared to baseline.
Figuras y tablas -
Analysis 13.8

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 8 Change in number of night‐time awakenings per week compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 9 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 13.9

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 9 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 10 Methacholine BHR (log base 2 PC20 FEV1 mg/ml).
Figuras y tablas -
Analysis 13.10

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 10 Methacholine BHR (log base 2 PC20 FEV1 mg/ml).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 11 Physician‐rated efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 13.11

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 11 Physician‐rated efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 12 Morning plasma cortisol (mcg/dL).
Figuras y tablas -
Analysis 13.12

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 12 Morning plasma cortisol (mcg/dL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 13 Change in morning plasma cortisol compared to baseline (mcg/dL).
Figuras y tablas -
Analysis 13.13

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 13 Change in morning plasma cortisol compared to baseline (mcg/dL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 14 8 hour area under curve (AUC) plasma cortisol during 6 hour 250 mcg co‐syntropin infusion (mcg hour/dL).
Figuras y tablas -
Analysis 13.14

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 14 8 hour area under curve (AUC) plasma cortisol during 6 hour 250 mcg co‐syntropin infusion (mcg hour/dL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 15 Peak plasma cortisol during during 6 hour 250 mcg co‐syntropin infusion (mcg/dL).
Figuras y tablas -
Analysis 13.15

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 15 Peak plasma cortisol during during 6 hour 250 mcg co‐syntropin infusion (mcg/dL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 16 Withdrawal due to clinical asthma exacerbation (No. of patients).
Figuras y tablas -
Analysis 13.16

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 16 Withdrawal due to clinical asthma exacerbation (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 17 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 13.17

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 17 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 18 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 13.18

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 18 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 19 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 13.19

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 19 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 20 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 13.20

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 20 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 21 HRQOL: AQLQ.
Figuras y tablas -
Analysis 13.21

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 21 HRQOL: AQLQ.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 22 Log PD20 mg.
Figuras y tablas -
Analysis 13.22

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 22 Log PD20 mg.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 23 FVC (absolute values ‐ Litres).
Figuras y tablas -
Analysis 13.23

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 23 FVC (absolute values ‐ Litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 24 Withdrawals (any reason).
Figuras y tablas -
Analysis 13.24

Comparison 13 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages), Outcome 24 Withdrawals (any reason).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 1 FEV1 (litres).
Figuras y tablas -
Analysis 14.1

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 1 FEV1 (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 2 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 14.2

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 2 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 5 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 14.5

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 5 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 6 Change in evening PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 14.6

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 6 Change in evening PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 7 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 14.7

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 7 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 8 Change in number of night‐time awakening per week compared to baseline score.
Figuras y tablas -
Analysis 14.8

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 8 Change in number of night‐time awakening per week compared to baseline score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 9 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 14.9

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 9 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 11 Physician‐rated efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 14.11

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 11 Physician‐rated efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 17 Withdrawal due to lack of treatment efficacy (No.of patients).
Figuras y tablas -
Analysis 14.17

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 17 Withdrawal due to lack of treatment efficacy (No.of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 18 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 14.18

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 18 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 19 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 14.19

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 19 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 20 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 14.20

Comparison 14 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations), Outcome 20 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 1 FEV1 (litres).
Figuras y tablas -
Analysis 15.1

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 1 FEV1 (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 2 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 15.2

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 2 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 5 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 15.5

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 5 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 6 Change in evening PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 15.6

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 6 Change in evening PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 7 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 15.7

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 7 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 8 Change in night‐time awakening per week compared to baseline.
Figuras y tablas -
Analysis 15.8

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 8 Change in night‐time awakening per week compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 9 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 15.9

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 9 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 11 Physician‐rated efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 15.11

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 11 Physician‐rated efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 17 Withdrawal due to lack of treatment efficacy (No. of patients).
Figuras y tablas -
Analysis 15.17

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 17 Withdrawal due to lack of treatment efficacy (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 18 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 15.18

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 18 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 19 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 15.19

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 19 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 20 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 15.20

Comparison 15 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices), Outcome 20 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 1 FEV1 (litres).
Figuras y tablas -
Analysis 16.1

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 1 FEV1 (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 2 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 16.2

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 2 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 5 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 16.5

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 5 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 6 Change in evening PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 16.6

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 6 Change in evening PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 7 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 16.7

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 7 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 8 Change in night‐time wakening score.
Figuras y tablas -
Analysis 16.8

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 8 Change in night‐time wakening score.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 9 Change in daily use of beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 16.9

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 9 Change in daily use of beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 11 Physician‐rated efficacy: effective or very effective (No. of patients).
Figuras y tablas -
Analysis 16.11

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 11 Physician‐rated efficacy: effective or very effective (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 17 Withdrawal due to lack of treatment efficacy (No.of patients).
Figuras y tablas -
Analysis 16.17

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 17 Withdrawal due to lack of treatment efficacy (No.of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 18 Sore throat or pharyngitis (No. of patients).
Figuras y tablas -
Analysis 16.18

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 18 Sore throat or pharyngitis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 19 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 16.19

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 19 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 20 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 16.20

Comparison 16 FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity), Outcome 20 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 FP versus placebo: Parallel group studies, no oral steroids: 2000 mcg/d (all ages), Outcome 1 PD20 ‐ change from baseline.
Figuras y tablas -
Analysis 17.1

Comparison 17 FP versus placebo: Parallel group studies, no oral steroids: 2000 mcg/d (all ages), Outcome 1 PD20 ‐ change from baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 1 FEV1 (% predicted ‐ absolute values).
Figuras y tablas -
Analysis 18.1

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 1 FEV1 (% predicted ‐ absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 2 PEF (% predicted ‐ absolute values).
Figuras y tablas -
Analysis 18.2

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 2 PEF (% predicted ‐ absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 3 Quality of life (absolute scores ‐ AQLQ).
Figuras y tablas -
Analysis 18.3

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 3 Quality of life (absolute scores ‐ AQLQ).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 4 Symptoms.
Figuras y tablas -
Analysis 18.4

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 4 Symptoms.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 6 Rescue medication usage (unclear time frame ‐ absolute values).
Figuras y tablas -
Analysis 18.6

Comparison 18 FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages), Outcome 6 Rescue medication usage (unclear time frame ‐ absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages), Outcome 1 FEV1.
Figuras y tablas -
Analysis 19.1

Comparison 19 FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages), Outcome 1 FEV1.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages), Outcome 2 Throat irritation.
Figuras y tablas -
Analysis 19.2

Comparison 19 FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages), Outcome 2 Throat irritation.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages), Outcome 3 Upper respiratory tract infections.
Figuras y tablas -
Analysis 19.3

Comparison 19 FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages), Outcome 3 Upper respiratory tract infections.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages), Outcome 4 Lower respiratory tract infection.
Figuras y tablas -
Analysis 19.4

Comparison 19 FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages), Outcome 4 Lower respiratory tract infection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 20 FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages), Outcome 1 FEV1 (absolute values).
Figuras y tablas -
Analysis 20.1

Comparison 20 FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages), Outcome 1 FEV1 (absolute values).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 20 FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages), Outcome 2 PC 20.
Figuras y tablas -
Analysis 20.2

Comparison 20 FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages), Outcome 2 PC 20.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 20 FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages), Outcome 3 Cortisol suppression.
Figuras y tablas -
Analysis 20.3

Comparison 20 FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages), Outcome 3 Cortisol suppression.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 21 FP versus placebo: Crossover studies, no oral steroids: 1000mcg/d (all ages), Outcome 1 Cortisol suppression.
Figuras y tablas -
Analysis 21.1

Comparison 21 FP versus placebo: Crossover studies, no oral steroids: 1000mcg/d (all ages), Outcome 1 Cortisol suppression.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 21 FP versus placebo: Crossover studies, no oral steroids: 1000mcg/d (all ages), Outcome 2 PC 20.
Figuras y tablas -
Analysis 21.2

Comparison 21 FP versus placebo: Crossover studies, no oral steroids: 1000mcg/d (all ages), Outcome 2 PC 20.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 1 Number of patients able to discontinue OCS completely.
Figuras y tablas -
Analysis 22.1

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 1 Number of patients able to discontinue OCS completely.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 2 Change in daily dose of oral prednisolone compared to baseline (mg).
Figuras y tablas -
Analysis 22.2

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 2 Change in daily dose of oral prednisolone compared to baseline (mg).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 3 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 22.3

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 3 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 4 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 22.4

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 4 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 5 Change in evening PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 22.5

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 5 Change in evening PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 6 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 22.6

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 6 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 7 Change in daily use of rescue beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 22.7

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 7 Change in daily use of rescue beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 8 Asthma Quality of Life Questionnaire: change in overall score compared to baseline.
Figuras y tablas -
Analysis 22.8

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 8 Asthma Quality of Life Questionnaire: change in overall score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 9 Asthma Quality of Life Questionnaire: change in activity limitation domain compared to baseline.
Figuras y tablas -
Analysis 22.9

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 9 Asthma Quality of Life Questionnaire: change in activity limitation domain compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 10 Asthma Quality of Life Questionnaire: change in asthma symptoms domain compared to baseline.
Figuras y tablas -
Analysis 22.10

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 10 Asthma Quality of Life Questionnaire: change in asthma symptoms domain compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 11 Asthma Quality of Life Questionnaire: change in emotional function domain compared to baseline.
Figuras y tablas -
Analysis 22.11

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 11 Asthma Quality of Life Questionnaire: change in emotional function domain compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 12 Asthma Quality of Life Questionnaire: change in enviromental exposure domain compared to baseline.
Figuras y tablas -
Analysis 22.12

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 12 Asthma Quality of Life Questionnaire: change in enviromental exposure domain compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 14 Sore throat (No. of patients).
Figuras y tablas -
Analysis 22.14

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 14 Sore throat (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 15 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 22.15

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 15 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 17 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 22.17

Comparison 22 FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d, Outcome 17 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 1 Number of patients able to discontinue OCS completely.
Figuras y tablas -
Analysis 23.1

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 1 Number of patients able to discontinue OCS completely.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 2 Change in daily dose of oral prednisolone compared to baseline (mg).
Figuras y tablas -
Analysis 23.2

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 2 Change in daily dose of oral prednisolone compared to baseline (mg).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 3 Change in FEV1 compared to baseline (litres).
Figuras y tablas -
Analysis 23.3

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 3 Change in FEV1 compared to baseline (litres).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 4 Change in morning PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 23.4

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 4 Change in morning PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 5 Change in evening PEFR compared to baseline (L/min).
Figuras y tablas -
Analysis 23.5

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 5 Change in evening PEFR compared to baseline (L/min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 6 Change in daily asthma symptom score compared to baseline.
Figuras y tablas -
Analysis 23.6

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 6 Change in daily asthma symptom score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 7 Change in daily use of rescue beta2 agonist compared to baseline (puffs/d).
Figuras y tablas -
Analysis 23.7

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 7 Change in daily use of rescue beta2 agonist compared to baseline (puffs/d).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 8 Asthma Quality of Life Questionnaire: change in overall score compared to baseline.
Figuras y tablas -
Analysis 23.8

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 8 Asthma Quality of Life Questionnaire: change in overall score compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 9 Asthma Quality of Life Questionnaire: change in activity limitation domain compared to baseline.
Figuras y tablas -
Analysis 23.9

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 9 Asthma Quality of Life Questionnaire: change in activity limitation domain compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 10 Asthma Quality of Life Questionnaire: change in asthma symptoms domain compared to baseline.
Figuras y tablas -
Analysis 23.10

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 10 Asthma Quality of Life Questionnaire: change in asthma symptoms domain compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 11 Asthma Quality of Life Questionnaire: change in emotional function domain compared to baseline.
Figuras y tablas -
Analysis 23.11

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 11 Asthma Quality of Life Questionnaire: change in emotional function domain compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 12 Asthma Quality of Life Questionnaire: change in enviromental exposure domain compared to baseline.
Figuras y tablas -
Analysis 23.12

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 12 Asthma Quality of Life Questionnaire: change in enviromental exposure domain compared to baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 14 Sore throat (No. of patients).
Figuras y tablas -
Analysis 23.14

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 14 Sore throat (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 15 Hoarseness or dysphonia (No. of patients).
Figuras y tablas -
Analysis 23.15

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 15 Hoarseness or dysphonia (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 16 Oral Candidiasis (No. of patients).
Figuras y tablas -
Analysis 23.16

Comparison 23 FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d, Outcome 16 Oral Candidiasis (No. of patients).

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 1. Incomplete data not included in meta‐analysis

Study ID

Data

Allen 1997

Medical Outcomes Study Short Form (SF‐36A)
Living with asthma questionnaire
No SD values available for above outcomes

Sleep scale
No numerical data available for above outcome

Chervinsky 1994

Change in urinary free cortisol compared to baseline
Change in urinary 17‐hydroxy steroids compared to baseline
Change in morning plasma cortisol compared to baseline
Change in plasma cortisol 60 min post cosyntropin
No SD values available for above outcomes

Ekroos 1998

Histamine bronchial hyperresponsiveness (PD15 FEV1)
Log transformed data not available

Faul 1998

FEV1 (after treatment: baseline ratio)
FEV1/FVC (after treatment: baseline ratio)
FEF 25‐75 (after treatment: baseline ratio)
Histamine bronchial responsiveness PC20 FEV1 (after treatment: baseline ratio)
Results expressed using medians and ranges for above outcomes

Galant 1999

Morning plasma cortisol
No numerical data available

Hart 2000

FEV1(reported as non‐significant)
am PEF

Both outcomes recorded but no data presented.

Hofstra 2000

PD20

Unable to ascertain distribution around geometric mean

Hoekstra 1997

Night‐time (4am) PEFR
Morning serum cortisol
Morning urine cortisol (collection time frame not specified)
No SD values available for above outcomes

Jayaram 2002

All outcomes reported in study could not be entered as dosage was unclear.

Jeffery 2002

FEV1; am PEF

Recorded but not reported.

Katz 1998

Change in FEV1 compared to baseline
Change in FVC compared to baseline
Change in FEF25‐75 compared to baseline
Change in evening PEFR compared to baseline
Change in night‐time awakening score compared to baseline
No SD values available for above outcomes

Langley 2002

Rescue medication usage

Median values reported.

Lindqvist 2003

FEV1 ‐ change from baseline in L/min
Symptoms ‐ change from baseline
Medication usage ‐ change from baseline

No SDs presented

MacKenzie 1993

FEV1
Morning PEFR
Evening PEFR
Clinic PEFR
No SD values available for above outcomes

Daily asthma symptom score
Morning plasma cortisol
No numerical data available for above outcomes

Noonan 1998

Change in log e methacholine bronchial responsiveness PD20 FEV1
Error bars plotted on graphical display of results, but unclear whether these represent SD or SEM values

Olivieri 1997

Methacholine bronchial responsiveness PC20 FEV1
Randomised treatment groups were not compared: results expressed as change compared to baseline for each individual treatment group.

Overbeek 1996

Daily asthma symptom score
No numerical data available for above outcome

Pearlman 1997

Change in evening PEFR compared to baseline
No SD values available for above outcome

Morning serum cortisol
Plasma cortisol 30‐60 min post 250 mcg iv cosyntropin
No numerical data available for above outcome

Physician rated global assessment of efficacy
Data not presented in a form suitable for meta‐analysis

Wasserman 1996

Physician‐rated global assessment of effectiveness
Data not presented in a form suitable for meta‐analysis

Wolfe 1996

Change FEV1 compared to baseline
No SD values available for above outcome

Change in morning PEFR compared to baseline
Change in evening PEFR compared to baseline
Daily wheeze, cough, shortness of breath scores
Daily beta2 agonist use
Morning plasma cortisol
No numerical data available for above outcomes

Figuras y tablas -
Table 1. Incomplete data not included in meta‐analysis
Ir a la tabla de la revisión
Table 2. Search history detail

Issue of CLIB

Time frame of search

Search detail

Issue 3, 2001

All years to March 1999

Stage 1 electronic search: 6494 citations retrieved, 2162 unique citations imported to Inhaled Steroid Register; Stage 2 electronic search: Fluticasone Register: 258 citations (180 excluded on basis of abstract: 150 not RCT; 30 not chronic asthma in humans). 78 papers retrieved in full text form ‐ 50 excluded on full paper: 6 not RCT, 38 no randomised placebo arm, 2 treatment period < 1 week; 1 infants; 3 nebuliser delivery device; 28 papers meeting inclusion criteria; 21 unique studies meeting inclusion criteria. Other sources: Two studies (Galant 1999; Li 1999) were identified by GSK. These studies were published after the date of the final electronic search (March 1999). Five studies (Ekroos 1999; Hofstra 2000; Nathan 1999; Busse 2001; Van Schoor 2002) were identified as a result of searching respiratory society meeting abstracts.

Issue 2, 2005

March 1999 to January 2004

From handsearching the updated inhaled steroids search results (1301 additional references), a 'fluticasone' register was created consisting of 197 citations (121 references excluded from abstracts as irrelevant comparisons). Three studies reported data from two different trials each, and so two study identities were created for each study (Berger 2002 BD; Berger 2002 ICS; Sorkness 1999; Sorkness 1999a; Wolfe 2000 BD; Wolfe 2000 ICS). Seventy‐five references, pertaining to 55 studies were retrieved in full. We excluded studies for the following reasons: Wrong comparison (11); no clear diagnosis of asthma (2); acute asthma (1); not randomised (1). One study was a full published version of a previously included abstract (Busse 2001). Forty new studies were included in the January 2004 update:

Allen 2000; Arets 2002; Berger 2002 BD; Berger 2002 ICS; Casale 2001; Convery 2000; Corsico 2000; Derom 1999; Derom 2001; Falcoz 2000; Giannini 2003; Hart 2000; Jayaram 2002; Jeffery 2002; Kavuru 2000; Laforce 2000; Langley 2002; Lanz 2001; Li 1999a; Li 1999b; Lindqvist 2003; Micheletto 2000; Nathan 2000; Nielsen 2002; Parameswaren 2000; Pauwels 2002; Pearlman 1999; Pearlman 2002; Rooklin 2001; Shapiro 2000; Sorkness 1999; Sorkness 1999a; Sovijärvi 2003; van Grunsven 2000; van Rensen 1999; Ward 2001; Weinstein 2001; Wolfe 2000 BD; Wolfe 2000 ICS; ZuWallack 2000.

Issue 4, 2005

January 2004‐2005
Figuras y tablas -
Table 2. Search history detail
Ir a la tabla de la revisión
Table 3. Asthma severity: characteristics of included patients at baseline

Study ID

FEV1: incl. criteria

FEV1: mean baseline

Symptom frequency

OCS treatment

ICS treatment

Author opinion

Overall estimation

Agertoft 1997

Not stated

Not stated

No

Not stated

Mild

Mild

Allen 1998

>60

88‐89

Not stated

No

Approx. 50% patients ICS naive at baseline, 50% previous regular ICS use

Mild to moderate

Mild to moderate

Allen 2000

Not stated

61%

Not stated

Yes

Not stated

Not stated

Severe

Arets 2002

Not stated

99‐104

SABA >1600mcg/d during >30% days of last year excluded

No

Only ICS <100mcg/d

Mild

Mild

Berger 2002 BD

60‐85%

72‐71.9%

>/=2 puffs BD on 2 of last 7 days of run‐in; symptom scores >/=2 of last 7 days

No

Not within 1 month of study

Not stated

Mild to moderate

Berger 2002 ICS

60‐90%

75.9‐75.8%

</=30 puffs over past 7 days

No

For three months prior to randomisation

Not stated

Moderate

Boonsawat 2004

Not stated

Not stated

Requirement for SABAs alone

No

No

Mild

Mild

Busse 2001

50‐80

68‐69

Symptomatic despite treatment with short acting beta2 agonist

No

No

Not stated

Moderate

Casale 2001

>/=65%

3 Litres

Not stated

No

No

Mild to moderate

Mild to moderate

Chervinsky 1994

60‐90

71‐73

Not stated

No

Yes: at least 1 month regular treatment with BDP prior to study

Mild to moderate

Mild to moderate

Condemi 1997

50‐80

66‐68

"< 3 days needing > 12 puffs beta2 agonist in 7 days< 4 days with diurnal PEFR variability of > 20% in 7 days"

No

Yes: ICS for at least 1 month prior to study

Not stated

Moderate

Convery 2000

Not stated

100‐103

Not stated

Not stated

Not stated

Not stated

Mild

Corsico 2000

>80%

98‐102

Stable asthma for previous 2 months

Not stated

Not stated

Mild

Mild

Derom 1999

>/=40%

80%

Exacerbation free for 1 month

No

No

Not stated

Mild

Derom 2001

Not stated

Not stated

Not stated

Not stated

Not stated

Not stated

Unclear

Dorinsky 2004

50‐85%

Not stated

4 days of week preceding randomisation; pre‐treatment with SABA only

No

No

Not stated

Mild‐moderate

Ekroos 1999

Not stated

Not stated

Not stated

No

No

Mild

Mild

Falcoz 2000

50‐80%

Not stated

Not stated

Not stated

Not stated

Mild‐moderate

Mild‐moderate

Falcoz 2000a

50‐80%

Not stated

Not stated

Not stated

Not stated

Mild‐moderate

Mild‐moderate

Faul 1998

>40

73

Not stated

No

No

Not stated

Unclear

Galant 1999

50‐80

65‐67

"Mean beta2 agonist use 3.5 puffs/dMean night awakenings/week 0.05 to 0.08"

No

24‐30% of patients ICS treated

Mild to moderate

Mild to moderate

Galant 1996

45‐75

60‐62

> 8 puffs/d beta2 agonist or 2‐4 night‐time awakenings in week run‐in

No

No

Mild to moderate

Moderate

Giannini 2003

Not stated

3.23 L
96 % predicted

Use of ß‐agonist during run‐in (unspecified)

Not stated

Not stated

Mild‐moderate

Mild

Given 2004

Not stated

Not stated

Not stated

No

Not stated

Unclear

Unclear

Hart 2000

Not stated

98.5%

Not stated

Not stated

Not stated

Mild

Mild

Hoekstra 1996

>75

88‐92

Not stated

No

No

Moderate

Moderate

Hofstra 2000

Not stated

96.6‐93.2%

Not stated

No

No

Not stated

Unclear

Jayaram 2002

Not stated

Not stated

Not stated

Not stated

Not stated

Not stated

Unclear

Jeffery 2002

Not stated

75.6%

Not stated

No

No ‐ SABA treatment only

Not stated

Mild

Katz 1998

Not stated

PEFR 75 (% predicted) or less

Asthma symptoms on at least 4 out of 10 days of run in period or at least one night‐time awakening in 10 days or 4 or puffs beta2 agonist on at least 4 days

No

No

Not stated

Moderate

Kavuru 2000

40‐85% predicted

64% predicted

Participants excluded if excessive use of SABA during run‐in, and frequent nocturnal awakenings

No

Yes

Not stated

Moderate

Kemp 2004

50‐100% predicted

82‐85% predicted

Mild stable asthma

No

No

Mild

Mild

LaForce 2000

50‐85% predicted

70‐73% predicted

Participants had to have stable asthma during run‐in

No

Pharmacotherapy required for at least 3 months prior to the study (irresepective of whether ICS or not)

Not stated

Mild‐moderate

Langley 2002

>/=60%

93.5%

Not stated

No

No

Not stated

Mild

Lanz 2001

50‐85%

75%

Not stated

No

No

Moderate

Mild‐moderate

Lawrence 1997

50‐80%

65‐68

"Mean beta2 agonist use 3.2 ‐ 4.2 puffs/d "

No

Yes: 3 months treatment or longer prior to study

Not stated

Moderate

Li 1999

>60

91

Not stated

No

No

Mild

Mild

Li 1999a

>60%

80‐83%

Use of SABA on 50% days in run‐in

No

Yes ‐ 12 months with BDP up to 500mcg/d

Not stated

Moderate

Li 1999b

>/=50%

82‐89%

Not stated

Prednisolone </=140mg in past year or equivalent

No

Not stated

Mild‐moderate

Lindqvist 2003

60‐100%

79‐83%

Participants were to have been 'symptomatic'

No

No

Not stated

Mild

Lipworth 2005

>/=70%

82%

Use of SABA 2 x per week for 6 months

No

No

Mild to moderate

Mild

MacKenzie 1993

Not stated

Not stated

"Patients had experienced a worsening of asthma with deterioration in lung function leading to change in medication or hospitalisation in last monthsymptoms on at least 4 out of 7 days "

No

No

Moderate

Moderate

Michelletto 2000

Not stated

73‐74%

Not stated

Not stated

Not stated

Mild‐moderate

Unclear

Nathan 1999

Not stated

Not stated

Not stated

No

85% of patients receiving ICS

Not stated

Unclear

Nathan 2000

45‐75% predicted

63.3‐64.3

Not stated

No

Yes

Moderate

Moderate

Nelson 1999

40‐80

60‐62

Not stated

Yes

Almost 100% of patients receiving ICS

Severe

Severe

Nielsen 2002

Not stated

Not stated

Not stated

No

Yes

Not stated

Unclear

Noonan 1998

60‐85

73‐76

"No more than 12 puffs/d beta2 agonistand no more than 3 nights with awakening due to asthma"

No

No

Mild to moderate

Moderate

Noonan 1995

40‐80

56‐57.4

Requirement for rescue beta2 agonist for 2 weeks prior to study due to symptoms

Yes

87% of patients receiving ICS

Severe

Severe

Olivieri 1997

> 80

98

< 2 puffs/d beta2 agonist

No

No

Mild

Mild

O'Shaughnessy 1993

> 60

Not stated

No

No

Not stated

Mild

Mild

Overbeek 1996

Not stated

84‐86

Not stated

No

Not stated

Not stated

Mild

Parameswaren 2000

Not stated

90.2

Few or no symptoms

No

No

Mild

Mild

Pauwels 2002

Not stated

Not stated

Not stated

Not stated

Not stated

Not stated

Unclear

Pearlman 1997

50‐80

66‐67

"Mean beta2 agonist use 3.4‐4.1 puffs/dNo more than 12 puffs/d beta2 agonist and no more than 2 nights with awakening due to asthma symptoms in last 7 days"

No

Yes: at least 3 months

Moderate

Moderate

Pearlman 1999

50‐80% predicted

65‐69

No more than 12 puffs of SABA on more than 2 days during run‐in

No

Not in previous month

Not stated

Mild‐moderate

Pearlman 2002

45‐80% predicted

65.3‐65.6

Not stated

Not stated

Yes

Not stated

Moderate

Pearlman 2004

40‐85%

Not reported

Described as symptomatic

Not stated

Not stated

Not stated

Mild to moderate

Peden 1998

50‐85

72‐73

"No more than 12 puffs/d beta2 agonistand no more than 3 nights with awakening due to asthmaMean awakenings per night due to asthma 0.05 to 0.09Mean beta2 agonist use 1.4 to 2.0 puffs/d"

No

Some patients: amount and type of ICS not stated

Not stated

Moderate

Rooklin 2001

40‐85%

68%

Not stated

Not stated

Yes

Not stated

Moderate

SAS30021

Not stated (am PEF 50‐85% predicted)

Not stated (am PEF 75.2‐76.7% predicted)

Symptoms on >/=4 days of week prior to randomisation

No

No

Not stated

Mild

SAS30024

Not stated (pre‐BD PEF had to be >80% predicted)

3.1 Litres

0.57 puffs rescue medication per day

No

Not stated

Mild

Mild

Shapiro 2000

40‐85%

66‐68%

Not stated

No

Yes

Not stated

Moderate

Sheffer 1996

45‐75

62‐64

"During 7 day run‐in:> 2 night‐time awakenings due to asthma in last 7 days20% or greater PEFR diurnal variabilityat least one day in which 8 puffs beta2 agonist used "

No

No

Mild to moderate

Moderate

Sorkness 1999

>/=50%

83‐88%

Not stated

No

No

Mild to moderate

Mild to moderate

Sorkness 1999a

>/=50%

83‐88%

Not stated

No

No

Mild to moderate

Mild to moderate

Sovijärvi 2003

>/=65%

79‐84

Stable asthma

No

No

Mild

MIld

van Grunsven 2000

Not stated

93%

Not stated

Not stated

Not stated

Not stated

Mild to moderate

van Rensen 1999

>75%

95.6‐96.2%

Stable asthma

No

No

Not stated

Mild

Van Schoor 2002

Not stated

Not stated

Not stated

No

Not stated

Mild

Mild

Ward 2001

Not stated

91.3%

Mild to moderate symptomatic asthma

No

No

Mild to moderater

Mild to moderate

Wasserman 1996

50‐80

Not stated

"Mean beta2 agonist use 3.1 to 3.3 puffs/dDuring last 7 days run‐in no more than 12 puffs/d beta2 agonist and no more than 2 nights with awakening due to asthma"

No

No

Not stated

Moderate

Wolfe 1996

50‐80

64‐66

During 2 week run‐in period no more than 12 puffs/d beta2 agonist and no more than 2 nights with awakening due to asthma

No

Yes

Moderate

Moderate

Wolfe 2000 BD

50‐80

69

During 2 week run‐in: 0 days with >/= 12 puffs of SABA prn

No

No

Not stated

Mild‐moderate

Wolfe 2000 ICS

50‐80

70

During 2 week run‐in: 0 days with >/= 12 puffs of SABA prn

No

Yes ‐ for 3 months prior to study entry

Not stated

Moderate

ZuWallack 2000

50‐80%

66‐68%

Not stated

No

Yes

Not stated

Moderate
Figuras y tablas -
Table 3. Asthma severity: characteristics of included patients at baseline
Ir a la tabla de la revisión
Table 4. Criteria for trial withdrawal due to lack of efficacy

Study ID

FEV1

PEFR

Beta2 agonist use

Night‐time awakening

Exacerbations

Chervinsky 1994

20% or greater decrease compared to baseline

20% decrease in morning or evening PEFR on 4 or more days out of 7 in week prior to clinic visit

12 or more puffs on 3 or more days out of 7 in week prior to clinic visit

2 or more nights with 2 awakening out of 7 in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

Galant 1996

15% or greater decrease compared to baseline

20% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit

12 or more puffs on 3 or more days out of 7 in week prior to clinic visit

3 or more awakening in week prior to clinic visit

Katz 1997

15% or greater decrease compared to baseline

15% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit

8 or more puffs on 2 or more days out of 7 in week prior to clinic visit

2 or more nights with awakening out of 7 in week prior to clinic visit

Kavuru 2000

20% or greater decrease compared to baseline

20% or greater decrease from mean am PEF compared to baseline on 3 or more days out of 7 in week prior to clinic visit

12 or more puffs on 2 or more days out of 7 in week prior to clinic visit

2 or more awakening in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

Nathan 2000

20% or greater decrease compared to baseline

20% or greater decrease compared to baseline

12 or more puffs on 2 or more days out of 7 in week prior to clinic visit

2 or more awakening in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

Pearlman 1997

20% or greater decrease compared to baseline

20% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit

12 or more puffs on 2 or more days out of 7 in week prior to clinic visit

2 or more awakening in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

Peden 1997

15% or greater decrease compared to baseline

20% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit

12 or more puffs on 3 or more days out of 7 in week prior to clinic visit

3 or more awakening in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

Shapiro 2000

20% or greater decrease compared to baseline

20% or greater decrease compared to baseline on 3+ days out of preceding 7 prior to clinic visit

12 or more puffs on 2 or more days out of 7 in week prior to clinic visit

2 or more awakening in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

Sheffer 1996

15% or greater decrease compared to baseline

20% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit

12 or more puffs on 3 or more days out of 7 in week prior to clinic visit

3 or more nights with awakening out of 7 in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

Wolfe 2000 (BD and ICS studies)

20% or greater decrease compared to baseline

20% or greater decrease compared to baseline

12 or more puffs on 2 or more days out of 7 in week prior to clinic visit

2 or more awakening in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

ZuWallack 2000

20% or greater decrease compared to baseline

20% or greater decrease compared to baseline on 3+ days out of preceding 7 prior to clinic visit

12 or more puffs on 2 or more days out of 7 in week prior to clinic visit

2 or more awakening in week prior to clinic visit

Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist

Figuras y tablas -
Table 4. Criteria for trial withdrawal due to lack of efficacy
Ir a la tabla de la revisión
Table 5. Definitions of exacerbation leading to study withdrawal

Study ID

Definition

Allen 1998

Requirement for more than two 7‐day courses of oral corticosteroid for asthma exacerbation

Berger 2002

Requirement for treatmen with oral or parenteral steroids

Hoekstra 1996

Treatment with oral steroids

Oliveri 1997

Not given

Overbeek 1996

Not given

Pearlman 1999

Not given

Shapiro 2000

Requirement for emergency treatment, hospitalisation or usage of medication not allowed by study protocol

Figuras y tablas -
Table 5. Definitions of exacerbation leading to study withdrawal
Ir a la tabla de la revisión
Comparison 1. FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

9

1364

Mean Difference (IV, Fixed, 95% CI)

0.30 [0.25, 0.34]

1.1 Children

2

321

Mean Difference (IV, Fixed, 95% CI)

0.12 [0.04, 0.20]

1.2 Adults

7

1043

Mean Difference (IV, Fixed, 95% CI)

0.38 [0.32, 0.43]

2 Change in FEV1 compared to baseline (litres) Show forest plot

10

1673

Litres (Fixed, 95% CI)

0.21 [0.18, 0.25]

2.1 Children

2

321

Litres (Fixed, 95% CI)

0.11 [0.05, 0.18]

2.2 Adults

8

1352

Litres (Fixed, 95% CI)

0.26 [0.21, 0.31]

3 FEV1 ‐ Litres (absolute values) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Change in morning PEFR compared to baseline (L/min) Show forest plot

10

1705

Mean Difference (IV, Fixed, 95% CI)

22.79 [19.07, 26.51]

4.1 Children

2

353

Mean Difference (IV, Fixed, 95% CI)

26.41 [18.03, 34.79]

4.2 Adults

8

1352

Mean Difference (IV, Fixed, 95% CI)

21.91 [17.76, 26.06]

5 Change in am PEF (predicted) Show forest plot

1

% (Fixed, 95% CI)

Totals not selected

5.1 Children

1

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Adults

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Change in evening PEFR compared to baseline (L/min) Show forest plot

8

1794

Mean Difference (IV, Fixed, 95% CI)

11.46 [8.19, 14.74]

6.1 Children

2

780

Mean Difference (IV, Fixed, 95% CI)

6.98 [2.26, 11.71]

6.2 Adults

6

1014

Mean Difference (IV, Fixed, 95% CI)

15.60 [11.06, 20.15]

7 Change in evening PEFR compared to baseline Show forest plot

9

1954

Litres/min (Fixed, 95% CI)

12.08 [8.87, 15.30]

7.1 Children

2

780

Litres/min (Fixed, 95% CI)

6.98 [2.26, 11.70]

7.2 Adults

7

1174

Litres/min (Fixed, 95% CI)

16.51 [12.12, 20.91]

8 Change in evening PEF (predicted) Show forest plot

1

% (Fixed, 95% CI)

Totals not selected

8.1 Children

1

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 Adults

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Peak flow ‐ L/min (absolute values) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

9.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Change in clinic PEFR compared to baseline (L/min) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

10.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11 Change in FVC compared to baseline (litres) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

11.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Change in FEF25‐75 compared to baseline (L/second) Show forest plot

2

467

Mean Difference (IV, Fixed, 95% CI)

0.20 [0.05, 0.34]

12.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.2 Adults

2

467

Mean Difference (IV, Fixed, 95% CI)

0.20 [0.05, 0.34]

13 Change in daily asthma symptom score compared to baseline Show forest plot

8

1238

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.57 [‐0.69, ‐0.46]

13.1 Children

2

353

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.52 [‐0.73, ‐0.31]

13.2 Adults

6

885

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐0.73, ‐0.46]

14 Symptoms ‐ absolute scores Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

14.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

14.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

15 Change in night‐time wakening score Show forest plot

6

895

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐0.38, ‐0.12]

15.1 Children

1

176

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.29 [‐0.59, 0.01]

15.2 Adults

5

719

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.24 [‐0.39, ‐0.09]

16 Nighttime awakenings/night Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

16.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

16.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

17 Change in number night‐time wakenings per week Show forest plot

4

648

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.17, ‐0.05]

17.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

17.2 Adults

4

648

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.17, ‐0.05]

18 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

9

1839

Mean Difference (IV, Fixed, 95% CI)

‐0.94 [‐1.14, ‐0.74]

18.1 Children

3

957

Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐0.87, ‐0.33]

18.2 Adults

6

882

Mean Difference (IV, Fixed, 95% CI)

‐1.36 [‐1.66, ‐1.06]

19 Rescue medication usage ‐ puffs/d (absolute scores) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

19.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

19.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

20 HRQOL: AQLQ Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

20.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

20.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

21 HRQOL: Functional Status IIR questionaire (short version) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

21.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

21.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

22 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, burden dimension Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

22.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

22.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

23 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, subjective norms dimension Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

23.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

23.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

24 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, social dimension Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

24.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

24.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

25 HRQOL: Sleep Scale Children questionnaire Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

25.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

25.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

26 Physician‐rated efficacy: effective or very effective Show forest plot

4

664

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.12 [3.76, 6.98]

26.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

26.2 Adults

4

664

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.12 [3.76, 6.98]

27 Withdrawal due to clinical asthma exacerbation (No. of patients) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

27.1 Children

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

27.2 Adults

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

28 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

8

1479

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.26 [0.20, 0.32]

28.1 Children

2

353

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.32 [0.21, 0.49]

28.2 Adults

6

1126

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.23 [0.17, 0.31]

29 Withdrawals due to adverse events Show forest plot

3

957

Odds Ratio (M‐H, Fixed, 95% CI)

1.11 [0.38, 3.20]

29.1 Children

1

604

Odds Ratio (M‐H, Fixed, 95% CI)

1.24 [0.33, 4.65]

29.2 Adults

2

353

Odds Ratio (M‐H, Fixed, 95% CI)

0.90 [0.15, 5.43]

30 Morning plasma cortisol (mcg/dL) Show forest plot

2

197

Mean Difference (IV, Fixed, 95% CI)

0.27 [‐1.05, 1.59]

30.1 Children

1

159

Mean Difference (IV, Fixed, 95% CI)

0.70 [‐0.84, 2.24]

30.2 Adults

1

38

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐3.46, 1.66]

31 Total urinary free cortisol excretion (mcg/24 hours) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

31.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

31.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

32 Sore throat or pharyngitis (No. of patients) Show forest plot

6

1336

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.98 [0.97, 4.04]

32.1 Children

2

821

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.71 [0.73, 3.99]

32.2 Adults

4

515

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.82 [0.74, 10.75]

33 Hoarseness or dysphonia (No. of patients) Show forest plot

7

1215

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.00 [1.53, 16.37]

33.1 Children

2

395

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.19 [0.74, 69.93]

33.2 Adults

5

820

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.36 [1.09, 17.52]

34 Oral Candidiasis (No. of patients) Show forest plot

7

1298

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.45 [1.29, 9.26]

34.1 Children

3

653

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.98 [0.40, 9.85]

34.2 Adults

4

645

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.84 [1.39, 16.88]

35 Headaches Show forest plot

3

957

Odds Ratio (M‐H, Fixed, 95% CI)

0.82 [0.58, 1.17]

35.1 Children

1

604

Odds Ratio (M‐H, Fixed, 95% CI)

0.74 [0.50, 1.10]

35.2 Adults

2

353

Odds Ratio (M‐H, Fixed, 95% CI)

1.22 [0.57, 2.59]
Figuras y tablas -
Comparison 1. FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages)
Ir a la tabla de la revisión
Comparison 2. FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

10

1673

Litres (Fixed, 95% CI)

0.21 [0.18, 0.25]

1.1 1‐4 weeks

0

0

Litres (Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 1‐5 months

10

1673

Litres (Fixed, 95% CI)

0.21 [0.18, 0.25]

1.3 6 months or longer

0

0

Litres (Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Change in morning PEFR compared to baseline (L/min) Show forest plot

10

1705

Mean Difference (IV, Fixed, 95% CI)

22.79 [19.07, 26.51]

2.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 1‐5 months

10

1705

Mean Difference (IV, Fixed, 95% CI)

22.79 [19.07, 26.51]

2.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Change in evening PEFR compared to baseline Show forest plot

9

1954

Litres/min (Fixed, 95% CI)

12.08 [8.87, 15.30]

3.1 1‐4 weeks

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 1‐5 months

9

1954

Litres/min (Fixed, 95% CI)

12.08 [8.87, 15.30]

3.3 6 months or greater

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Change in daily asthma symptom score compared to baseline Show forest plot

8

1238

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.57 [‐0.69, ‐0.46]

4.1 1‐4 weeks

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 1‐5 months

8

1238

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.57 [‐0.69, ‐0.46]

4.3 6 months or longer

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5 Change in number night‐time wakenings per week Show forest plot

4

648

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.17, ‐0.05]

5.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 1‐5 months

4

648

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.17, ‐0.05]

5.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Change in night‐time wakening score Show forest plot

6

895

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐0.38, ‐0.12]

6.1 1‐4 weeks

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 1‐5 months

6

895

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐0.38, ‐0.12]

6.3 6 months or longer

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

9

1839

Mean Difference (IV, Fixed, 95% CI)

‐0.94 [‐1.14, ‐0.74]

7.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 1‐5 months

9

1839

Mean Difference (IV, Fixed, 95% CI)

‐0.94 [‐1.14, ‐0.74]

7.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Physician‐rated efficacy: effective or very effective Show forest plot

4

664

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.12 [3.76, 6.98]

8.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 1‐5 months

4

664

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.12 [3.76, 6.98]

8.3 6 months or greater

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

8

1479

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.26 [0.20, 0.32]

9.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 1‐5 months

8

1479

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.26 [0.20, 0.32]

9.3 6 months or greater

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Sore throat or pharyngitis (No. of patients) Show forest plot

6

1336

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.98 [0.97, 4.04]

10.1 1‐4 weeks

1

38

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.38 [0.31, 18.63]

10.2 1‐5 months

4

1081

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.71 [0.73, 3.98]

10.3 6 months or greater

1

217

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.24 [0.55, 19.04]

11 Hoarseness or dysphonia (No. of patients) Show forest plot

7

1215

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.00 [1.53, 16.37]

11.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 1‐5 months

6

998

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.36 [1.09, 17.52]

11.3 6 months or greater

1

217

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.19 [0.74, 69.93]

12 Oral Candidiasis (No. of patients) Show forest plot

7

1298

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.45 [1.29, 9.26]

12.1 1‐4 weeks

1

258

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.00, 6.93]

12.2 1‐5 months

5

823

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.77 [1.21, 11.79]

12.3 6 months or greater

1

217

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.19 [0.74, 69.93]

13 Withdrawals due to adverse events Show forest plot

3

957

Odds Ratio (M‐H, Fixed, 95% CI)

1.11 [0.38, 3.20]

13.1 1‐4 weeks

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

13.2 1‐5 months

3

957

Odds Ratio (M‐H, Fixed, 95% CI)

1.11 [0.38, 3.20]

13.3 6 months or greater

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 2. FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all treatment durations)
Ir a la tabla de la revisión
Comparison 3. FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

10

1673

Litres (Fixed, 95% CI)

0.21 [0.18, 0.25]

1.1 MDI

4

559

Litres (Fixed, 95% CI)

0.40 [0.32, 0.48]

1.2 DPI

6

1114

Litres (Fixed, 95% CI)

0.16 [0.12, 0.21]

2 Change in morning PEFR compared to baseline (L/min) Show forest plot

10

1705

Mean Difference (IV, Fixed, 95% CI)

22.79 [19.07, 26.51]

2.1 MDI

5

868

Mean Difference (IV, Fixed, 95% CI)

17.86 [12.36, 23.35]

2.2 DPI

5

837

Mean Difference (IV, Fixed, 95% CI)

26.98 [21.92, 32.04]

3 Change in evening PEFR compared to baseline Show forest plot

9

1954

Litres/min (Fixed, 95% CI)

12.08 [8.87, 15.30]

3.1 MDI

3

381

Litres/min (Fixed, 95% CI)

19.11 [12.08, 26.14]

3.2 DPI

6

1573

Litres/min (Fixed, 95% CI)

10.22 [6.61, 13.84]

4 Change in daily asthma symptom score compared to baseline Show forest plot

8

1238

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.57 [‐0.69, ‐0.46]

4.1 MDI

4

559

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.52 [‐0.69, ‐0.35]

4.2 DPI

4

679

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.62 [‐0.78, ‐0.47]

5 Change in number night‐time wakenings per week Show forest plot

4

648

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.17, ‐0.05]

5.1 MDI

3

488

Mean Difference (IV, Fixed, 95% CI)

‐0.09 [‐0.16, ‐0.02]

5.2 DPI

1

160

Mean Difference (IV, Fixed, 95% CI)

‐0.18 [‐0.31, ‐0.05]

6 Change in night‐time wakening score Show forest plot

6

895

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐0.38, ‐0.12]

6.1 MDI

4

559

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.18 [‐0.35, ‐0.02]

6.2 DPI

2

336

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.36 [‐0.58, ‐0.14]

7 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

9

1839

Mean Difference (IV, Fixed, 95% CI)

‐0.94 [‐1.14, ‐0.74]

7.1 MDI

4

559

Mean Difference (IV, Fixed, 95% CI)

‐1.11 [‐1.48, ‐0.74]

7.2 DPI

5

1280

Mean Difference (IV, Fixed, 95% CI)

‐0.87 [‐1.11, ‐0.63]

8 Physician‐rated efficacy: effective or very effective Show forest plot

4

664

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.12 [3.76, 6.98]

8.1 MDI

2

336

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.15 [3.31, 8.02]

8.2 DPI

2

328

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.09 [3.30, 7.85]

9 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

8

1479

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.26 [0.20, 0.32]

9.1 MDI

4

801

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.23 [0.16, 0.33]

9.2 DPI

4

678

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.28 [0.20, 0.38]

10 Sore throat or pharyngitis (No. of patients) Show forest plot

6

1336

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.98 [0.97, 4.04]

10.1 MDI

2

187

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.02 [0.49, 18.64]

10.2 DPI

4

1149

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.83 [0.84, 3.98]

11 Hoarseness or dysphonia (No. of patients) Show forest plot

7

1215

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.00 [1.53, 16.37]

11.1 MDI

3

492

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.71 [0.74, 18.49]

11.2 DPI

4

723

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.15 [1.23, 41.51]

12 Oral Candidiasis (No. of patients) Show forest plot

7

1298

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.45 [1.29, 9.26]

12.1 MDI

2

317

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.19 [0.54, 18.68]

12.2 DPI

5

981

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.58 [1.09, 11.75]

13 Withdrawals due to adverse events Show forest plot

3

957

Odds Ratio (M‐H, Fixed, 95% CI)

1.11 [0.38, 3.20]

13.1 MDI

2

353

Odds Ratio (M‐H, Fixed, 95% CI)

0.90 [0.15, 5.43]

13.2 DPI

1

604

Odds Ratio (M‐H, Fixed, 95% CI)

1.24 [0.33, 4.65]
Figuras y tablas -
Comparison 3. FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all delivery devices)
Ir a la tabla de la revisión
Comparison 4. FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

10

1673

Litres (Fixed, 95% CI)

0.21 [0.18, 0.25]

1.1 Mild

1

309

Litres (Fixed, 95% CI)

0.02 [‐0.06, 0.10]

1.2 Mild to moderate

1

158

Litres (Fixed, 95% CI)

0.35 [0.19, 0.51]

1.3 Moderate

8

1206

Litres (Fixed, 95% CI)

0.26 [0.22, 0.31]

2 Change in morning PEFR compared to baseline (L/min) Show forest plot

10

1705

Mean Difference (IV, Fixed, 95% CI)

22.79 [19.07, 26.51]

2.1 Mild

1

309

Mean Difference (IV, Fixed, 95% CI)

8.60 [0.84, 16.36]

2.2 Mild to moderate

1

158

Mean Difference (IV, Fixed, 95% CI)

30.0 [17.98, 42.02]

2.3 Moderate

8

1238

Mean Difference (IV, Fixed, 95% CI)

26.61 [22.08, 31.14]

3 Change in evening PEFR compared to baseline Show forest plot

9

1954

Litres/min (Fixed, 95% CI)

12.08 [8.87, 15.30]

3.1 Mild

2

913

Litres/min (Fixed, 95% CI)

5.92 [1.52, 10.33]

3.2 Mild to moderate

1

158

Litres/min (Fixed, 95% CI)

30.00 [19.32, 40.68]

3.3 Moderate

6

883

Litres/min (Fixed, 95% CI)

16.51 [11.26, 21.76]

7 Change in daily asthma symptom score compared to baseline Show forest plot

8

1238

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.57 [‐0.69, ‐0.46]

7.1 Mild

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 Mild to moderate

1

158

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.53 [‐0.85, ‐0.21]

7.3 Moderate

7

1080

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.58 [‐0.70, ‐0.46]

8 Change in number night‐time wakenings per week Show forest plot

4

648

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.17, ‐0.05]

8.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 Mild to moderate

1

158

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.25, 0.01]

8.3 Moderate

3

490

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.18, ‐0.04]

9 Change in night‐time wakening score Show forest plot

6

895

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐0.38, ‐0.12]

9.1 Mild

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Mild to moderate

1

158

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.29 [‐0.61, 0.02]

9.3 Moderate

5

737

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.24 [‐0.38, ‐0.09]

10 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

9

1839

Mean Difference (IV, Fixed, 95% CI)

‐0.94 [‐1.14, ‐0.74]

10.1 Mild

1

604

Mean Difference (IV, Fixed, 95% CI)

‐0.40 [‐0.76, ‐0.04]

10.2 Mild to moderate

1

158

Mean Difference (IV, Fixed, 95% CI)

‐0.83 [‐1.38, ‐0.28]

10.3 Moderate

7

1077

Mean Difference (IV, Fixed, 95% CI)

‐1.26 [‐1.52, ‐0.99]

16 Physician‐rated efficacy: effective or very effective Show forest plot

4

664

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.12 [3.76, 6.98]

16.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

16.2 Mild to moderate

1

158

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.06 [2.65, 9.67]

16.3 Moderate

3

506

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.14 [3.61, 7.31]

18 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

8

1479

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.26 [0.20, 0.32]

18.1 Mild

1

313

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.53 [0.15, 379.73]

18.2 Mild to moderate

1

158

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.11, 0.38]

18.3 Moderate

6

1008

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.26 [0.20, 0.34]

21 Sore throat or pharyngitis (No. of patients) Show forest plot

6

1336

Odds Ratio (M‐H, Fixed, 95% CI)

1.95 [0.93, 4.06]

21.1 Mild

1

604

Odds Ratio (M‐H, Fixed, 95% CI)

1.42 [0.53, 3.79]

21.2 Mild to moderate

2

255

Odds Ratio (M‐H, Fixed, 95% CI)

3.31 [0.66, 16.51]

21.3 Moderate

3

477

Odds Ratio (M‐H, Fixed, 95% CI)

2.41 [0.46, 12.65]

22 Hoarseness or dysphonia (No. of patients) Show forest plot

7

1215

Odds Ratio (M‐H, Fixed, 95% CI)

3.50 [1.06, 11.52]

22.1 Mild

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

22.2 Mild to moderate

2

382

Odds Ratio (M‐H, Fixed, 95% CI)

4.99 [0.58, 43.17]

22.3 Moderate

5

833

Odds Ratio (M‐H, Fixed, 95% CI)

2.91 [0.69, 12.29]

23 Oral Candidiasis (No. of patients) Show forest plot

7

1298

Odds Ratio (M‐H, Fixed, 95% CI)

2.81 [1.05, 7.48]

23.1 Mild

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

23.2 Mild to moderate

3

560

Odds Ratio (M‐H, Fixed, 95% CI)

3.08 [0.61, 15.51]

23.3 Moderate

4

738

Odds Ratio (M‐H, Fixed, 95% CI)

2.65 [0.77, 9.11]

24 Withdrawals due to adverse events Show forest plot

3

957

Odds Ratio (M‐H, Fixed, 95% CI)

1.11 [0.38, 3.20]

24.1 Mild

2

917

Odds Ratio (M‐H, Fixed, 95% CI)

0.99 [0.32, 3.11]

24.2 Mild to moderate

1

40

Odds Ratio (M‐H, Fixed, 95% CI)

2.33 [0.09, 60.84]

24.3 Moderate

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 4. FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all degrees asthma severity)
Ir a la tabla de la revisión
Comparison 5. FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

21

4790

Mean Difference (IV, Fixed, 95% CI)

0.24 [0.21, 0.26]

1.1 Children

2

331

Mean Difference (IV, Fixed, 95% CI)

0.19 [0.12, 0.25]

1.2 Adults

19

4459

Mean Difference (IV, Fixed, 95% CI)

0.25 [0.22, 0.27]

2 Change in FEV1 compared to baseline (imputed estimates) Show forest plot

22

4936

Litres (Fixed, 95% CI)

0.24 [0.21, 0.26]

2.1 Children

3

477

Litres (Fixed, 95% CI)

0.18 [0.13, 0.24]

2.2 Adults

19

4459

Litres (Fixed, 95% CI)

0.25 [0.22, 0.28]

3 Change in FEV1 (% predicted) Show forest plot

5

674

% (Fixed, 95% CI)

9.95 [7.98, 11.91]

3.1 Children

2

192

% (Fixed, 95% CI)

11.28 [7.62, 14.94]

3.2 Adults

3

482

% (Fixed, 95% CI)

9.41 [7.07, 11.74]

4 Change in FEV1 (%) Show forest plot

2

280

Mean Difference (IV, Fixed, 95% CI)

13.05 [7.85, 18.25]

4.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Adults

2

280

Mean Difference (IV, Fixed, 95% CI)

13.05 [7.85, 18.25]

5 FEV1 (% predicted ‐ absolute values) Show forest plot

4

157

% (Fixed, 95% CI)

4.22 [0.94, 7.50]

5.1 Children

3

125

% (Fixed, 95% CI)

5.92 [2.22, 9.62]

5.2 Adults

1

32

% (Fixed, 95% CI)

‐2.0 [‐9.08, 5.08]

6 FEV1 (absolute values) Show forest plot

2

86

Litres (Fixed, 95% CI)

0.06 [‐0.00, 0.13]

6.1 Children

1

68

Litres (Fixed, 95% CI)

0.06 [‐0.00, 0.12]

6.2 Adults

1

18

Litres (Fixed, 95% CI)

0.59 [‐0.31, 1.49]

7 Change in morning PEFR compared with baseline Show forest plot

24

5117

Litres/min (Fixed, 95% CI)

26.96 [24.51, 29.40]

7.1 Children

5

611

Litres/min (Fixed, 95% CI)

25.68 [20.09, 31.27]

7.2 Adults

19

4506

Litres/min (Fixed, 95% CI)

27.26 [24.54, 29.98]

8 Change in morning PEFR compared to baseline (L/min) Show forest plot

21

3752

Mean Difference (IV, Fixed, 95% CI)

29.29 [26.44, 32.14]

8.1 Children

3

509

Mean Difference (IV, Fixed, 95% CI)

27.50 [20.79, 34.21]

8.2 Adults

18

3243

Mean Difference (IV, Fixed, 95% CI)

29.69 [26.54, 32.83]

9 Mean change in am PEF (% predicted) Show forest plot

2

665

% (Fixed, 95% CI)

4.49 [2.92, 6.05]

9.1 Children

1

241

% (Fixed, 95% CI)

6.0 [2.08, 9.92]

9.2 Adults

1

424

% (Fixed, 95% CI)

4.2 [2.49, 5.91]

10 Change in evening PEFR compared to baseline (L/min) Show forest plot

15

3118

Mean Difference (IV, Fixed, 95% CI)

21.33 [18.26, 24.40]

10.1 Children

2

331

Mean Difference (IV, Fixed, 95% CI)

20.77 [13.06, 28.47]

10.2 Adults

13

2787

Mean Difference (IV, Fixed, 95% CI)

21.44 [18.09, 24.79]

11 Change in evening PEFR compared to baseline Show forest plot

16

3283

Litres/min (Fixed, 95% CI)

21.59 [18.55, 24.62]

11.1 Children

2

331

Litres/min (Fixed, 95% CI)

20.77 [13.07, 28.46]

11.2 Adults

14

2952

Litres/min (Fixed, 95% CI)

21.74 [18.44, 25.03]

12 Change in clinic PEFR compared to baseline (L/min) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

12.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

13 Peak flow L/min (absolute values) Show forest plot

2

50

Mean Difference (IV, Fixed, 95% CI)

68.07 [7.89, 128.25]

13.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

13.2 Adults

2

50

Mean Difference (IV, Fixed, 95% CI)

68.07 [7.89, 128.25]

14 Change in FVC compared to baseline (litres) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

14.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

14.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

15 Change in FEF25‐75 compared to baseline (L/second) Show forest plot

2

1423

Mean Difference (IV, Fixed, 95% CI)

0.25 [0.16, 0.34]

15.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

15.2 Adults

2

1423

Mean Difference (IV, Fixed, 95% CI)

0.25 [0.16, 0.34]

16 Histamine BHR (log base 2 PC20 FEV1 mg/ml) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

16.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

16.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

17 Change in daily asthma symptom score compared to baseline Show forest plot

20

3671

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.49 [‐0.56, ‐0.43]

17.1 Children

3

509

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.55 [‐0.72, ‐0.37]

17.2 Adults

17

3162

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.48 [‐0.56, ‐0.41]

18 Change in night‐time wakening score Show forest plot

6

884

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.45 [‐0.59, ‐0.32]

18.1 Children

1

173

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.41 [‐0.71, ‐0.11]

18.2 Adults

5

711

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.47 [‐0.62, ‐0.32]

19 Change in symptom free days Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

19.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

19.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

20 Change from baseline in symptom free days (%) Show forest plot

3

971

Mean Difference (IV, Fixed, 95% CI)

7.03 [3.31, 10.75]

20.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

20.2 Adults

3

971

Mean Difference (IV, Fixed, 95% CI)

7.03 [3.31, 10.75]

21 Percentage nights without awakening ‐ change from baseline Show forest plot

2

208

Mean Difference (IV, Fixed, 95% CI)

10.65 [4.84, 16.46]

21.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

21.2 Adults

2

208

Mean Difference (IV, Fixed, 95% CI)

10.65 [4.84, 16.46]

22 Change in number night‐time wakenings per week Show forest plot

4

641

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.23, ‐0.12]

22.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

22.2 Adults

4

641

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.23, ‐0.12]

23 Change from baseline in nighttime awakenings/night Show forest plot

5

1359

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.17, ‐0.08]

23.1 Children

1

158

Mean Difference (IV, Fixed, 95% CI)

‐0.1 [‐0.16, ‐0.04]

23.2 Adults

4

1201

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.24, ‐0.09]

24 Change in nocturnal awakenings (unspecified time) Show forest plot

2

280

Mean Difference (IV, Fixed, 95% CI)

‐0.07 [‐0.11, ‐0.02]

24.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

24.2 Adults

2

280

Mean Difference (IV, Fixed, 95% CI)

‐0.07 [‐0.11, ‐0.02]

25 Symptoms (absolute values) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

25.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

25.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

26 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

20

4899

Mean Difference (IV, Fixed, 95% CI)

‐1.20 [‐1.34, ‐1.05]

26.1 Children

3

509

Mean Difference (IV, Fixed, 95% CI)

‐1.04 [‐1.39, ‐0.70]

26.2 Adults

17

4390

Mean Difference (IV, Fixed, 95% CI)

‐1.23 [‐1.39, ‐1.07]

27 Change in daily use of beta2 agonist compared to baseline (puffs/d ‐ imputed estimates) Show forest plot

22

5111

Mean Difference (IV, Fixed, 95% CI)

‐1.01 [‐1.13, ‐0.88]

27.1 Children

3

509

Mean Difference (IV, Fixed, 95% CI)

‐1.04 [‐1.39, ‐0.70]

27.2 Adults

19

4602

Mean Difference (IV, Fixed, 95% CI)

‐1.00 [‐1.13, ‐0.87]

28 Change from baseline in rescue medication free days (%) Show forest plot

2

809

Mean Difference (IV, Fixed, 95% CI)

10.49 [5.48, 15.51]

28.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

28.2 Adults

2

809

Mean Difference (IV, Fixed, 95% CI)

10.49 [5.48, 15.51]

29 Rescue medication (absolute scores) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

29.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

29.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

30 HRQOL: AQLQ (absolute socres) Show forest plot

3

513

Mean Difference (IV, Fixed, 95% CI)

0.68 [0.49, 0.87]

30.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

30.2 Adults

3

513

Mean Difference (IV, Fixed, 95% CI)

0.68 [0.49, 0.87]

31 HRQOL: Functional Status IIR questionaire (short version) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

31.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

31.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

32 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, burden dimension Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

32.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

32.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

33 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, subjective norms dimension Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

33.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

33.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

34 HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, social dimension Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

34.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

34.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

35 HRQOL: Sleep Scale Children questionnaire Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

35.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

35.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

36 Physician‐rated efficacy: effective or very effective (No. of patients) Show forest plot

3

568

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.83 [4.16, 8.16]

36.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

36.2 Adults

3

568

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.83 [4.16, 8.16]

37 Exacerbations requiring OCS treatment Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

37.1 Children

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

37.2 Adults

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

38 Withdrawal due to clinical asthma exacerbation (No. of patients) Show forest plot

4

702

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.12, 0.39]

38.1 Children

2

248

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.18 [0.09, 0.38]

38.2 Adults

2

454

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.29 [0.11, 0.79]

39 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

17

4071

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.17, 0.24]

39.1 Children

2

351

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.13, 0.31]

39.2 Adults

15

3720

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.21 [0.17, 0.25]

40 Withdrawals (any reason) Show forest plot

8

2080

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.40 [0.31, 0.51]

40.1 Children

1

158

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.33 [0.18, 0.61]

40.2 Adults

7

1922

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.42 [0.32, 0.54]

41 Withdrawals due to adverse events Show forest plot

13

3595

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.31 [0.76, 2.27]

41.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

41.2 Adults

13

3595

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.31 [0.76, 2.27]

42 Adverse events (any) Show forest plot

4

884

Odds Ratio (M‐H, Fixed, 95% CI)

1.13 [0.84, 1.52]

42.1 Children

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

42.2 Adults

4

884

Odds Ratio (M‐H, Fixed, 95% CI)

1.13 [0.84, 1.52]

43 Oral Candidiasis (No. of patients) Show forest plot

13

1887

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.55 [1.43, 4.56]

43.1 Children

3

395

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.38 [0.54, 3.57]

43.2 Adults

10

1492

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.68 [1.76, 7.67]

44 Sore throat or pharyngitis (No. of patients) Show forest plot

17

3480

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.82 [1.27, 2.60]

44.1 Children

2

372

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.38 [0.54, 3.54]

44.2 Adults

15

3108

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.91 [1.29, 2.80]

45 Headaches Show forest plot

10

2602

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.07 [0.83, 1.38]

45.1 Children

1

158

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.39 [0.43, 4.50]

45.2 Adults

9

2444

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.06 [0.81, 1.37]

46 Hoarseness or dysphonia (No. of patients) Show forest plot

10

1645

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.34 [2.83, 14.21]

46.1 Children

2

394

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.10 [0.83, 79.01]

46.2 Adults

8

1251

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.12 [2.58, 14.51]

47 Upper respiratory tract infection Show forest plot

3

1623

Odds Ratio (M‐H, Fixed, 95% CI)

1.07 [0.76, 1.49]

47.1 Children

1

158

Odds Ratio (M‐H, Fixed, 95% CI)

0.97 [0.41, 2.31]

47.2 Adults

2

1465

Odds Ratio (M‐H, Fixed, 95% CI)

1.08 [0.75, 1.55]

48 Sinusitis Show forest plot

5

2030

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.29 [0.84, 1.99]

48.1 Children

1

158

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.69 [0.60, 4.74]

48.2 Adults

4

1872

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.22 [0.76, 1.96]

49 Total urinary free cortisol excretion (mcg/24 hours) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

49.1 Children

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

49.2 Adults

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

50 AUC serum cortisol (ng*h/mL) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

50.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

50.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

51 Morning plasma cortisol (mcg/dL) Show forest plot

2

194

Mean Difference (IV, Fixed, 95% CI)

0.00 [‐1.33, 1.33]

51.1 Children

1

154

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐1.23, 1.83]

51.2 Adults

1

40

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐3.57, 1.77]

52 Change in morning plasma cortisol compared to baseline (mcg/dL) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

52.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

52.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

53 Change in peak plasma cortisol expression (mcg/dL) Show forest plot

2

117

Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐2.56, 1.36]

53.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

53.2 Adults

2

117

Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐2.56, 1.36]
Figuras y tablas -
Comparison 5. FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages)
Ir a la tabla de la revisión
Comparison 6. FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

22

4936

Litres (Fixed, 95% CI)

0.24 [0.21, 0.26]

1.1 1‐4 weeks

1

46

Litres (Fixed, 95% CI)

0.27 [0.05, 0.49]

1.2 1‐5 months

20

3627

Litres (Fixed, 95% CI)

0.27 [0.24, 0.29]

1.3 6 months or longer

1

1263

Litres (Fixed, 95% CI)

0.1 [0.04, 0.16]

2 Change in FEV1 (% predicted) Show forest plot

5

674

% (Fixed, 95% CI)

9.95 [7.98, 11.91]

2.1 1‐4 weeks

0

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 1‐5 months

5

674

% (Fixed, 95% CI)

9.95 [7.98, 11.91]

2.3 6 months or longer

0

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Change in morning PEFR compared with baseline Show forest plot

24

5117

Litres/min (Fixed, 95% CI)

26.96 [24.51, 29.40]

3.1 1‐4 weeks

1

46

Litres/min (Fixed, 95% CI)

11.0 [‐9.83, 31.83]

3.2 1‐5 months

22

3808

Litres/min (Fixed, 95% CI)

29.03 [26.27, 31.80]

3.3 6 months or longer

1

1263

Litres/min (Fixed, 95% CI)

20.1 [14.70, 25.50]

4 Change in evening PEFR compared to baseline Show forest plot

16

3283

Litres/min (Fixed, 95% CI)

21.59 [18.55, 24.62]

4.1 1‐4 weeks

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 1‐5 months

16

3283

Litres/min (Fixed, 95% CI)

21.59 [18.55, 24.62]

4.3 6 months or longer

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

5 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

22

5111

Mean Difference (IV, Fixed, 95% CI)

‐1.01 [‐1.13, ‐0.88]

5.1 1‐4 weeks

1

46

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐1.73, ‐0.07]

5.2 1‐5 months

20

3802

Mean Difference (IV, Fixed, 95% CI)

‐1.25 [‐1.39, ‐1.11]

5.3 6 months or longer

1

1263

Mean Difference (IV, Fixed, 95% CI)

‐0.18 [‐0.44, 0.08]

6 HRQOL: AQLQ Show forest plot

3

513

Mean Difference (IV, Fixed, 95% CI)

0.68 [0.49, 0.87]

6.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 1‐5 months

3

513

Mean Difference (IV, Fixed, 95% CI)

0.68 [0.49, 0.87]

6.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Change in daily asthma symptom score compared to baseline Show forest plot

20

3671

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.49 [‐0.56, ‐0.43]

7.1 1‐4 weeks

1

46

Std. Mean Difference (IV, Fixed, 95% CI)

0.20 [‐0.37, 0.78]

7.2 1‐5 months

19

3625

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.50 [‐0.57, ‐0.44]

7.3 6 months or longer

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Change from baseline in symptom free days (%) Show forest plot

3

971

Mean Difference (IV, Fixed, 95% CI)

7.03 [3.31, 10.75]

8.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 1‐5 months

3

971

Mean Difference (IV, Fixed, 95% CI)

7.03 [3.31, 10.75]

8.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Change in night‐time wakening score Show forest plot

6

884

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.45 [‐0.59, ‐0.32]

9.1 1‐4 weeks

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 1‐5 months

6

884

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.45 [‐0.59, ‐0.32]

9.3 6 months or longer

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Change from baseline in nighttime awakenings/night Show forest plot

5

1359

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.17, ‐0.08]

10.1 1‐4 weeks

1

158

Mean Difference (IV, Fixed, 95% CI)

‐0.1 [‐0.16, ‐0.04]

10.2 1‐5 months

4

1201

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.24, ‐0.09]

10.3 6 months or more

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11 Change in number night‐time wakenings per week Show forest plot

4

641

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.23, ‐0.12]

11.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 1‐5 months

4

641

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.23, ‐0.12]

11.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Physician‐rated efficacy: effective or very effective (No. of patients) Show forest plot

3

568

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.83 [4.16, 8.16]

12.3 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.4 1‐5 months

3

568

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.83 [4.16, 8.16]

12.5 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

13 Withdrawal due to clinical asthma exacerbation (No. of patients) Show forest plot

4

702

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.12, 0.39]

13.1 1‐4 weeks

1

46

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.00, 6.82]

13.2 1‐5 months

2

442

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.26 [0.10, 0.66]

13.3 6 months or longer

1

214

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.19 [0.09, 0.42]

14 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

17

4071

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.17, 0.24]

14.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

14.2 1‐5 months

15

2667

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.17, 0.24]

14.3 6 months or longer

2

1404

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.28 [0.08, 1.00]

15 Withdrawals due to adverse events Show forest plot

13

3595

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.31 [0.76, 2.27]

15.1 1‐4 weeks

4

203

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.20 [0.74, 69.96]

15.2 1‐5 months

7

1988

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.13 [0.56, 2.27]

15.3 6 months or longer

2

1404

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.30 [0.50, 3.33]

16 Withdrawals (any reason) Show forest plot

8

2080

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.40 [0.31, 0.51]

16.1 1‐4 weeks

2

117

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.78 [0.63, 22.68]

16.2 1‐5 months

5

664

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.29 [0.21, 0.40]

16.3 6 months or longer

1

1299

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.61 [0.41, 0.90]

17 Sore throat or pharyngitis (No. of patients) Show forest plot

17

3480

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.82 [1.27, 2.60]

17.1 1‐4 weeks

4

203

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.99 [0.24, 4.10]

17.2 1‐5 months

10

1669

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.88 [1.15, 3.08]

17.3 6 months or longer

3

1608

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.91 [1.09, 3.35]

18 Hoarseness or dysphonia (No. of patients) Show forest plot

10

1645

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.34 [2.83, 14.21]

18.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

18.2 1‐5 months

8

1322

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.25 [2.69, 14.52]

18.3 6 months or longer

2

323

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.46, 119.72]

19 Oral Candidiasis (No. of patients) Show forest plot

13

1887

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.55 [1.43, 4.56]

19.1 1‐4 weeks

1

60

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.92 [0.16, 399.84]

19.2 1‐5 months

10

1504

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.36 [1.30, 4.31]

19.3 6 months or longer

2

323

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.25 [0.45, 116.00]

20 Headaches Show forest plot

10

2602

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.07 [0.83, 1.38]

20.1 1‐4 weeks

3

157

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.73 [0.90, 50.54]

20.2 1‐5 months

6

1160

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.10 [0.75, 1.62]

20.3 6 months or longer

1

1285

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.99 [0.70, 1.41]

21 Sinusitis Show forest plot

5

2030

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.29 [0.84, 1.99]

21.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

21.2 1‐5 months

4

745

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.64 [0.95, 2.85]

21.3 6 months or longer

1

1285

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.89 [0.44, 1.77]
Figuras y tablas -
Comparison 6. FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all treatment durations)
Ir a la tabla de la revisión
Comparison 7. FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

22

4936

Litres (Fixed, 95% CI)

0.24 [0.21, 0.26]

1.1 MDI

9

1337

Litres (Fixed, 95% CI)

0.38 [0.33, 0.43]

1.2 DPI

13

3599

Litres (Fixed, 95% CI)

0.19 [0.16, 0.22]

2 Change in FEV1 (% predicted) Show forest plot

5

674

% (Fixed, 95% CI)

9.95 [7.98, 11.91]

2.1 MDI

1

202

% (Fixed, 95% CI)

10.5 [7.19, 13.81]

2.2 DPI

4

472

% (Fixed, 95% CI)

9.65 [7.20, 12.09]

3 Change in morning PEFR compared with baseline Show forest plot

24

5117

Litres/min (Fixed, 95% CI)

26.96 [24.51, 29.40]

3.1 MDI

10

1452

Litres/min (Fixed, 95% CI)

29.45 [24.97, 33.93]

3.2 DPI

14

3665

Litres/min (Fixed, 95% CI)

25.90 [22.98, 28.82]

4 Change in evening PEFR compared to baseline Show forest plot

16

3283

Litres/min (Fixed, 95% CI)

21.59 [18.55, 24.62]

4.1 MDI

5

787

Litres/min (Fixed, 95% CI)

27.98 [22.34, 33.62]

4.2 DPI

11

2496

Litres/min (Fixed, 95% CI)

18.99 [15.40, 22.59]

5 Change in daily asthma symptom score compared to baseline Show forest plot

20

3671

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.49 [‐0.56, ‐0.43]

5.1 MDI

7

1004

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.44 [‐0.57, ‐0.32]

5.2 DPI

12

2635

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.51 [‐0.59, ‐0.43]

5.3 Unclear

1

32

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Change from baseline in symptom free days (%) Show forest plot

3

971

Mean Difference (IV, Fixed, 95% CI)

7.03 [3.31, 10.75]

6.4 MDI

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.5 DPI

3

971

Mean Difference (IV, Fixed, 95% CI)

7.03 [3.31, 10.75]

7 Change from baseline in nighttime awakenings/night Show forest plot

5

1359

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.17, ‐0.08]

7.1 MDI

1

227

Mean Difference (IV, Fixed, 95% CI)

‐0.15 [‐0.30, 0.00]

7.2 DPI

4

1132

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.17, ‐0.07]

8 Change in number night‐time wakenings per week Show forest plot

4

641

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.23, ‐0.12]

8.1 MDI

3

485

Mean Difference (IV, Fixed, 95% CI)

‐0.15 [‐0.21, ‐0.09]

8.2 DPI

1

156

Mean Difference (IV, Fixed, 95% CI)

‐0.24 [‐0.34, ‐0.14]

9 Change in night‐time wakening score Show forest plot

6

884

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.45 [‐0.59, ‐0.32]

9.1 MDI

4

555

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.39 [‐0.56, ‐0.22]

9.2 DPI

2

329

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.56 [‐0.78, ‐0.34]

10 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

22

5111

Mean Difference (IV, Fixed, 95% CI)

‐1.01 [‐1.13, ‐0.88]

10.1 MDI

8

1184

Mean Difference (IV, Fixed, 95% CI)

‐1.35 [‐1.60, ‐1.10]

10.2 DPI

14

3927

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐1.04, ‐0.76]

11 HRQOL: AQLQ Show forest plot

3

513

Mean Difference (IV, Fixed, 95% CI)

0.68 [0.49, 0.87]

11.4 MDI

3

513

Mean Difference (IV, Fixed, 95% CI)

0.68 [0.49, 0.87]

11.5 DPI

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Physician‐rated efficacy: effective or very effective (No. of patients) Show forest plot

3

568

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.83 [4.16, 8.16]

12.1 MDI

3

568

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.83 [4.16, 8.16]

12.2 DPI

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

13 Withdrawal due to clinical asthma exacerbation (No. of patients) Show forest plot

4

702

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.12, 0.39]

13.1 MDI

1

46

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.00, 6.82]

13.2 DPI

3

656

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.12, 0.40]

14 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

17

4071

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.17, 0.24]

14.1 MDI

7

1105

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.19 [0.14, 0.24]

14.2 DPI

10

2966

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.17, 0.28]

15 Withdrawals due to adverse events Show forest plot

13

3595

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.31 [0.76, 2.27]

15.1 MDI

6

778

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.35 [0.43, 4.21]

15.2 DPI

7

2817

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.30 [0.70, 2.42]

16 Withdrawals (any reason) Show forest plot

8

2080

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.40 [0.31, 0.51]

16.1 MDI

2

226

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.21 [0.12, 0.37]

16.2 DPI

6

1854

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.46 [0.35, 0.61]

17 Sore throat or pharyngitis (No. of patients) Show forest plot

17

3480

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.82 [1.27, 2.60]

17.1 MDI

8

1085

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.21 [1.26, 3.89]

17.2 DPI

9

2395

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.60 [1.01, 2.53]

18 Hoarseness or dysphonia (No. of patients) Show forest plot

10

1645

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.34 [2.83, 14.21]

18.1 MDI

5

757

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.74 [2.13, 15.45]

18.2 DPI

5

888

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.72 [1.92, 31.07]

19 Oral Candidiasis (No. of patients) Show forest plot

13

1887

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.55 [1.43, 4.56]

19.1 MDI

6

834

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.26 [1.17, 9.06]

19.2 DPI

7

1053

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.27 [1.12, 4.59]

20 Headaches Show forest plot

10

2602

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.07 [0.83, 1.38]

20.1 MDI

4

446

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.07 [0.61, 1.87]

20.2 DPI

6

2156

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.07 [0.80, 1.43]

21 Sinusitis Show forest plot

5

2030

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.29 [0.84, 1.99]

21.1 MDI

3

587

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.63 [0.85, 3.11]

21.2 DPI

2

1443

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.08 [0.61, 1.92]
Figuras y tablas -
Comparison 7. FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all delivery devices)
Ir a la tabla de la revisión
Comparison 8. FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

22

4936

Litres (Fixed, 95% CI)

0.24 [0.21, 0.26]

1.1 Mild

1

1263

Litres (Fixed, 95% CI)

0.1 [0.04, 0.16]

1.2 Mild to moderate

8

1320

Litres (Fixed, 95% CI)

0.26 [0.22, 0.31]

1.3 Moderate

13

2353

Litres (Fixed, 95% CI)

0.27 [0.23, 0.30]

2 Change in FEV1 (% predicted) Show forest plot

5

674

% (Fixed, 95% CI)

9.95 [7.98, 11.91]

2.1 Mild

0

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Mild to moderate

2

304

% (Fixed, 95% CI)

10.08 [6.69, 13.48]

2.3 Moderate

3

370

% (Fixed, 95% CI)

9.88 [7.47, 12.29]

3 Change in morning PEFR compared with baseline Show forest plot

24

5117

Litres/min (Fixed, 95% CI)

26.96 [24.51, 29.40]

3.1 Mild

2

1331

Litres/min (Fixed, 95% CI)

19.35 [14.47, 24.24]

3.2 Mild to moderate

6

1094

Litres/min (Fixed, 95% CI)

24.48 [19.32, 29.64]

3.3 Moderate

16

2692

Litres/min (Fixed, 95% CI)

31.64 [28.27, 35.01]

4 Change in evening PEFR compared to baseline Show forest plot

16

3283

Litres/min (Fixed, 95% CI)

21.59 [18.55, 24.62]

4.1 Mild

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Mild to moderate

5

1305

Litres/min (Fixed, 95% CI)

18.22 [13.35, 23.09]

4.3 Moderate

11

1978

Litres/min (Fixed, 95% CI)

23.72 [19.84, 27.59]

5 Change in daily asthma symptom score compared to baseline Show forest plot

20

3671

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.49 [‐0.56, ‐0.43]

5.1 Mild

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Mild to moderate

7

1518

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.43 [‐0.53, ‐0.33]

5.3 Moderate

13

2153

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.54 [‐0.63, ‐0.45]

6 Change from baseline in symptom free days (%) Show forest plot

3

971

Mean Difference (IV, Fixed, 95% CI)

7.03 [3.31, 10.75]

6.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Mild to moderate

1

408

Mean Difference (IV, Fixed, 95% CI)

4.0 [‐1.02, 9.02]

6.3 Moderate

2

563

Mean Difference (IV, Fixed, 95% CI)

10.72 [5.18, 16.27]

7 Change in number night‐time wakenings per week Show forest plot

4

641

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.23, ‐0.12]

7.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 Mild to moderate

1

160

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.27, ‐0.07]

7.3 Moderate

3

481

Mean Difference (IV, Fixed, 95% CI)

‐0.17 [‐0.24, ‐0.11]

8 Change from baseline in nighttime awakenings/night Show forest plot

5

1359

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.17, ‐0.08]

8.1 MDI

1

227

Mean Difference (IV, Fixed, 95% CI)

‐0.15 [‐0.30, 0.00]

8.2 DPI

4

1132

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.17, ‐0.07]

9 Change in night‐time wakening score Show forest plot

6

884

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.45 [‐0.59, ‐0.32]

9.1 Mild

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Mild to moderate

1

160

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.53 [‐0.84, ‐0.21]

9.3 Moderate

5

724

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.44 [‐0.59, ‐0.29]

10 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

22

5111

Mean Difference (IV, Fixed, 95% CI)

‐1.01 [‐1.13, ‐0.88]

10.1 Mild

1

1263

Mean Difference (IV, Fixed, 95% CI)

‐0.18 [‐0.44, 0.08]

10.2 Mild to moderate

7

1518

Mean Difference (IV, Fixed, 95% CI)

‐0.89 [‐1.10, ‐0.68]

10.3 Moderate

14

2330

Mean Difference (IV, Fixed, 95% CI)

‐1.50 [‐1.68, ‐1.31]

11 HRQOL: AQLQ Show forest plot

3

513

Mean Difference (IV, Fixed, 95% CI)

0.68 [0.49, 0.87]

11.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 Mild to moderate

1

168

Mean Difference (IV, Fixed, 95% CI)

0.49 [0.17, 0.81]

11.3 Moderate

1

175

Mean Difference (IV, Fixed, 95% CI)

0.83 [0.48, 1.18]

11.4 Unclear

1

170

Mean Difference (IV, Fixed, 95% CI)

0.75 [0.43, 1.07]

12 Physician‐rated efficacy: effective or very effective (No. of patients) Show forest plot

3

568

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.83 [4.16, 8.16]

12.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.2 Mild to moderate

1

168

Peto Odds Ratio (Peto, Fixed, 95% CI)

10.01 [5.46, 18.37]

12.3 Moderate

2

400

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.58 [3.05, 6.86]

13 Withdrawal due to clinical asthma exacerbation (No. of patients) Show forest plot

4

702

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.12, 0.39]

13.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

13.2 Mild to moderate

3

668

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.12, 0.42]

13.3 Moderate

1

34

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.02, 1.11]

14 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

17

4071

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.17, 0.24]

14.1 Mild

2

1404

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.28 [0.08, 1.00]

14.2 Mild to moderate

4

906

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.21 [0.14, 0.30]

14.3 Moderate

11

1761

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.17, 0.25]

15 Withdrawals due to adverse events Show forest plot

13

3595

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.31 [0.76, 2.27]

15.1 Mild

3

1444

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.40 [0.56, 3.51]

15.2 Mild to moderate

6

1171

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.34 [0.50, 3.58]

15.3 Moderate

4

980

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.21 [0.48, 3.07]

16 Withdrawals (any reason) Show forest plot

8

2080

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.40 [0.31, 0.51]

16.1 Mild

1

1299

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.61 [0.41, 0.90]

16.2 Mild to moderate

5

467

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.39 [0.25, 0.60]

16.3 Moderate

2

314

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.25 [0.16, 0.39]

17 Sore throat or pharyngitis (No. of patients) Show forest plot

17

3480

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.82 [1.27, 2.60]

17.1 Mild

2

1394

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.97 [1.11, 3.49]

17.2 Mild to moderate

7

751

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.37 [0.75, 2.53]

17.3 Moderate

8

1335

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.32 [1.16, 4.64]

18 Hoarseness or dysphonia (No. of patients) Show forest plot

10

1645

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.34 [2.83, 14.21]

18.1 Mild

1

109

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.46, 119.72]

18.2 Mild to moderate

2

382

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.22 [0.14, 363.83]

18.3 Moderate

7

1154

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.21 [2.62, 14.72]

19 Oral Candidiasis (No. of patients) Show forest plot

13

1887

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.55 [1.43, 4.56]

19.1 Mild

1

109

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.26 [0.14, 365.74]

19.2 Mild to moderate

4

600

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.65 [0.67, 4.06]

19.3 Moderate

7

1155

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.39 [1.56, 7.36]

19.4 Unclear

1

23

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

20 Headaches Show forest plot

10

2602

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.07 [0.83, 1.38]

20.1 Mild

1

1285

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.99 [0.70, 1.41]

20.2 Mild to moderate

7

965

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.12 [0.73, 1.72]

20.3 Moderate

2

352

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.39 [0.61, 3.19]

21 Sinusitis Show forest plot

5

2030

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.29 [0.84, 1.99]

21.1 Mild

1

1285

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.89 [0.44, 1.77]

21.2 Mild to moderate

2

338

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.36 [0.61, 3.03]

21.3 Moderate

2

407

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.94 [0.91, 4.14]
Figuras y tablas -
Comparison 8. FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all degrees asthma severity)
Ir a la tabla de la revisión
Comparison 9. FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

6

872

Mean Difference (IV, Fixed, 95% CI)

0.44 [0.39, 0.50]

1.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Adults

6

872

Mean Difference (IV, Fixed, 95% CI)

0.44 [0.39, 0.50]

2 FEV1 (% predicted ‐ absolute scores) Show forest plot

2

50

Mean Difference (IV, Fixed, 95% CI)

24.43 [15.90, 32.95]

2.1 Children

1

26

Mean Difference (IV, Fixed, 95% CI)

4.30 [‐25.66, 34.26]

2.2 Adults

1

24

Mean Difference (IV, Fixed, 95% CI)

26.20 [17.31, 35.09]

3 Change in morning PEF Show forest plot

8

1116

Litres/min (Fixed, 95% CI)

40.44 [35.43, 45.45]

3.1 Children

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Adults

8

1116

Litres/min (Fixed, 95% CI)

40.44 [35.43, 45.45]

4 Change in morning PEFR compared to baseline (L/min) Show forest plot

7

1076

Mean Difference (IV, Fixed, 95% CI)

40.12 [35.06, 45.17]

4.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Adults

7

1076

Mean Difference (IV, Fixed, 95% CI)

40.12 [35.06, 45.17]

5 Change in am PEF (% predicted) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Change in evening PEF compared with baseline Show forest plot

4

515

Litres/min (Fixed, 95% CI)

30.20 [22.52, 37.87]

6.1 Children

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Adults

4

515

Litres/min (Fixed, 95% CI)

30.20 [22.52, 37.87]

7 Change in evening PEF compared with baseline (L/min) Show forest plot

3

354

Mean Difference (IV, Fixed, 95% CI)

28.96 [20.86, 37.06]

7.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 Adults

3

354

Mean Difference (IV, Fixed, 95% CI)

28.96 [20.86, 37.06]

8 Change in daily asthma symptom score compared to baseline Show forest plot

4

685

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.85 [‐1.01, ‐0.70]

8.1 Children

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 Adults

4

685

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.85 [‐1.01, ‐0.70]

9 Change in number night‐time wakenings per week Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

9.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Change in number of night‐time awakenings per night Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

10.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11 Change in % nights with no awakenings Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

11.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Change in night‐time wakening score Show forest plot

2

351

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐0.96, ‐0.52]

12.1 Children

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.2 Adults

2

351

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐0.96, ‐0.52]

13 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

4

682

Mean Difference (IV, Fixed, 95% CI)

‐2.22 [‐2.59, ‐1.84]

13.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

13.2 Adults

4

682

Mean Difference (IV, Fixed, 95% CI)

‐2.22 [‐2.59, ‐1.84]

14 Change in percentage of symptom free days compared to baseline Show forest plot

2

361

Mean Difference (IV, Fixed, 95% CI)

21.32 [13.54, 29.09]

14.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

14.2 Adults

2

361

Mean Difference (IV, Fixed, 95% CI)

21.32 [13.54, 29.09]

15 Change in percentage of rescue beta2 agonist free days compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

15.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

15.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

16 HRQOL: AQLQ Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

16.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

16.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

17 Physician rated global efficacy: effective or very effective (No. of patients) Show forest plot

3

480

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.86 [4.09, 8.39]

17.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

17.2 Adults

3

480

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.86 [4.09, 8.39]

18 Withdrawal due to clinical asthma exacerbation (No. of patients) Show forest plot

2

191

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.40 [0.17, 0.98]

18.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

18.2 Adults

2

191

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.40 [0.17, 0.98]

19 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

5

847

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.10, 0.18]

19.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

19.2 Adults

5

847

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.10, 0.18]

20 Withdrawals (total) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

20.1 Children

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

20.2 Adults

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

21 Sore throat or pharyngitis (No. of patients) Show forest plot

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.49 [1.11, 18.13]

21.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

21.2 Adults

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.49 [1.11, 18.13]

22 Hoarseness or dysphonia (No. of patients) Show forest plot

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.36 [2.65, 20.46]

22.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

22.2 Adults

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.36 [2.65, 20.46]

23 Oral Candidiasis (No. of patients) Show forest plot

5

841

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.37 [2.62, 15.48]

23.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

23.2 Adults

5

841

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.37 [2.62, 15.48]

25 No. patients with </=18 mcg/dL poststimulation cortisol Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

25.1 Children

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

25.2 Adults

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

26 Plasma cortisol (AUC) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

26.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

26.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 9. FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages)
Ir a la tabla de la revisión
Comparison 10. FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

6

872

Mean Difference (IV, Fixed, 95% CI)

0.44 [0.39, 0.50]

1.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 1‐5 months

6

872

Mean Difference (IV, Fixed, 95% CI)

0.44 [0.39, 0.50]

1.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Change in morning PEFR compared to baseline Show forest plot

8

1116

Litres/min (Fixed, 95% CI)

40.44 [35.43, 45.45]

2.1 1‐4 weeks

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 1‐5 months

8

1116

Litres/min (Fixed, 95% CI)

40.44 [35.43, 45.45]

2.3 6 months or longer

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Change in evening PEF compared with baseline (L/min) Show forest plot

3

354

Mean Difference (IV, Fixed, 95% CI)

28.96 [20.86, 37.06]

3.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 1‐5 months

3

354

Mean Difference (IV, Fixed, 95% CI)

28.96 [20.86, 37.06]

3.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Change in daily asthma symptom score compared to baseline Show forest plot

4

685

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.85 [‐1.01, ‐0.70]

4.1 1‐4 weeks

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 1‐5 months

4

685

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.85 [‐1.01, ‐0.70]

4.3 6 months or longer

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5 Change in night‐time wakening score Show forest plot

2

351

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐0.96, ‐0.52]

5.1 1‐4 weeks

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 1‐5 months

2

351

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐0.96, ‐0.52]

5.3 6 months or longer

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

4

682

Mean Difference (IV, Fixed, 95% CI)

‐2.22 [‐2.59, ‐1.84]

6.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 1‐5 months

4

682

Mean Difference (IV, Fixed, 95% CI)

‐2.22 [‐2.59, ‐1.84]

6.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Physician rated global efficacy: effective or very effective (No. of patients) Show forest plot

3

480

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.86 [4.09, 8.39]

9.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 1‐5 months

3

480

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.86 [4.09, 8.39]

9.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

4

676

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.12 [0.09, 0.17]

11.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 1‐5 months

4

676

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.12 [0.09, 0.17]

11.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Sore throat or pharyngitis (No. of patients) Show forest plot

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.49 [1.11, 18.13]

12.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.2 1‐5 months

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.49 [1.11, 18.13]

12.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

13 Hoarseness or dysphonia (No. of patients) Show forest plot

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.36 [2.65, 20.46]

13.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

13.2 1‐5 months

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.36 [2.65, 20.46]

13.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

14 Oral Candidiasis (No. of patients) Show forest plot

5

841

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.37 [2.62, 15.48]

14.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

14.2 1‐5 months

5

841

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.37 [2.62, 15.48]

14.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 10. FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all treatment durations)
Ir a la tabla de la revisión
Comparison 11. FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

6

872

Mean Difference (IV, Fixed, 95% CI)

0.44 [0.39, 0.50]

1.1 MDI

1

26

Mean Difference (IV, Fixed, 95% CI)

0.46 [0.29, 0.63]

1.2 DPI

5

846

Mean Difference (IV, Fixed, 95% CI)

0.44 [0.38, 0.50]

2 Change in morning PEFR compared with baseline Show forest plot

8

1116

Litres/min (Fixed, 95% CI)

40.44 [35.43, 45.45]

2.1 MDI

2

230

Litres/min (Fixed, 95% CI)

34.84 [23.10, 46.58]

2.2 DPI

6

886

Litres/min (Fixed, 95% CI)

41.69 [36.15, 47.23]

3 Change in evening PEF compared with baseline (L/min) Show forest plot

3

354

Mean Difference (IV, Fixed, 95% CI)

28.96 [20.86, 37.06]

3.1 MDI

1

23

Mean Difference (IV, Fixed, 95% CI)

8.3 [‐12.40, 29.00]

3.2 1DPI

2

331

Mean Difference (IV, Fixed, 95% CI)

32.69 [23.90, 41.49]

4 Change in daily asthma symptom score compared to baseline Show forest plot

4

685

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.85 [‐1.01, ‐0.70]

4.1 MDI

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 DPI

4

685

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.85 [‐1.01, ‐0.70]

5 Change in night‐time wakening score Show forest plot

2

351

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐0.96, ‐0.52]

5.1 MDI

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 DPI

2

351

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐0.96, ‐0.52]

6 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

4

682

Mean Difference (IV, Fixed, 95% CI)

‐2.22 [‐2.59, ‐1.84]

6.1 MDI

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 DPI

4

682

Mean Difference (IV, Fixed, 95% CI)

‐2.22 [‐2.59, ‐1.84]

9 Physician rated global efficacy: effective or very effective (No. of patients) Show forest plot

3

480

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.86 [4.09, 8.39]

9.1 MDI

1

147

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.23 [2.74, 10.00]

9.2 DPI

2

333

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.16 [4.00, 9.49]

10 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

4

676

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.12 [0.09, 0.17]

10.1 MDI

1

147

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.11 [0.06, 0.21]

10.2 DPI

3

529

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.13 [0.09, 0.18]

11 Sore throat or pharyngitis (No. of patients) Show forest plot

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.49 [1.11, 18.13]

11.1 MDI

1

147

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 DPI

3

523

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.49 [1.11, 18.13]

12 Hoarseness or dysphonia (No. of patients) Show forest plot

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.36 [2.65, 20.46]

12.1 MDI

1

147

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.93 [0.81, 77.43]

12.2 DPI

3

523

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.23 [2.30, 22.68]

13 Oral Candidiasis (No. of patients) Show forest plot

5

841

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.37 [2.62, 15.48]

13.1 MDI

1

147

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.93 [0.81, 77.43]

13.2 DPI

4

694

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.12 [2.33, 16.07]
Figuras y tablas -
Comparison 11. FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all delivery devices)
Ir a la tabla de la revisión
Comparison 12. FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in FEV1 compared to baseline (litres) Show forest plot

6

872

Mean Difference (IV, Fixed, 95% CI)

0.44 [0.39, 0.50]

1.1 Mild

1

26

Mean Difference (IV, Fixed, 95% CI)

0.46 [0.29, 0.63]

1.2 Mild to moderate

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.3 Moderate

5

846

Mean Difference (IV, Fixed, 95% CI)

0.44 [0.38, 0.50]

2 Change in morning PEFR compared with baseline Show forest plot

8

1116

Litres/min (Fixed, 95% CI)

40.44 [35.43, 45.45]

2.1 Mild

2

63

Litres/min (Fixed, 95% CI)

32.91 [12.00, 53.81]

2.2 Mild to moderate

0

0

Litres/min (Fixed, 95% CI)

0.0 [0.0, 0.0]

2.3 Moderate

6

1053

Litres/min (Fixed, 95% CI)

40.90 [35.74, 46.06]

3 Change in evening PEF compared with baseline (L/min) Show forest plot

3

354

Mean Difference (IV, Fixed, 95% CI)

28.96 [20.86, 37.06]

3.1 Mild

1

23

Mean Difference (IV, Fixed, 95% CI)

8.3 [‐12.40, 29.00]

3.2 Mild to moderate

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.3 Moderate

2

331

Mean Difference (IV, Fixed, 95% CI)

32.69 [23.90, 41.49]

4 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

4

682

Mean Difference (IV, Fixed, 95% CI)

‐2.22 [‐2.59, ‐1.84]

4.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Mild to moderate

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.3 Moderate

4

682

Mean Difference (IV, Fixed, 95% CI)

‐2.22 [‐2.59, ‐1.84]

5 Change in night‐time wakening score Show forest plot

2

351

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐0.96, ‐0.52]

5.1 Mild

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Mild to moderate

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.3 Moderate

2

351

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐0.96, ‐0.52]

6 Change in daily asthma symptom score compared to baseline Show forest plot

4

685

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.85 [‐1.01, ‐0.70]

6.1 Mild

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Mild to moderate

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.3 Moderate

4

685

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.85 [‐1.01, ‐0.70]

7 Physician rated global efficacy: effective or very effective (No. of patients) Show forest plot

3

480

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.86 [4.09, 8.39]

7.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 Mild to moderate

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.3 Moderate

3

480

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.86 [4.09, 8.39]

8 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

3

506

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.12 [0.09, 0.18]

8.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 Mild to moderate

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.3 Moderate

3

506

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.12 [0.09, 0.18]

9 Sore throat or pharyngitis (No. of patients) Show forest plot

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.49 [1.11, 18.13]

9.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Mild to moderate

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.3 Moderate

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.49 [1.11, 18.13]

10 Hoarseness or dysphonia (No. of patients) Show forest plot

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.36 [2.65, 20.46]

10.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.2 Mild to moderate

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.3 Moderate

4

670

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.36 [2.65, 20.46]

11 Oral Candidiasis (No. of patients) Show forest plot

5

841

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.37 [2.62, 15.48]

11.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 Mild to moderate

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.3 Moderate

5

841

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.37 [2.62, 15.48]
Figuras y tablas -
Comparison 12. FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all degrees asthma severity)
Ir a la tabla de la revisión
Comparison 13. FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 FEV1 (litres) Show forest plot

3

73

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.22, 0.48]

1.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Adults

3

73

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.22, 0.48]

2 Change in FEV1 compared to baseline (litres) Show forest plot

3

414

Mean Difference (IV, Fixed, 95% CI)

0.53 [0.43, 0.63]

2.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Adults

3

414

Mean Difference (IV, Fixed, 95% CI)

0.53 [0.43, 0.63]

3 Change in FVC compared to baseline (litres) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Change in FEF25‐75 compared to baseline (L/second) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

4.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5 Change in morning PEFR compared to baseline (L/min) Show forest plot

4

624

Mean Difference (IV, Fixed, 95% CI)

46.85 [39.64, 54.07]

5.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Adults

4

624

Mean Difference (IV, Fixed, 95% CI)

46.85 [39.64, 54.07]

6 Change in evening PEFR compared to baseline (L/min) Show forest plot

2

278

Mean Difference (IV, Fixed, 95% CI)

41.12 [31.36, 50.87]

6.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Adults

2

278

Mean Difference (IV, Fixed, 95% CI)

41.12 [31.36, 50.87]

7 Change in daily asthma symptom score compared to baseline Show forest plot

3

412

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.65 [‐0.85, ‐0.46]

7.1 Children

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 Adults

3

412

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.65 [‐0.85, ‐0.46]

8 Change in number of night‐time awakenings per week compared to baseline Show forest plot

2

277

Mean Difference (IV, Fixed, 95% CI)

‐0.18 [‐0.25, ‐0.11]

8.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 Adults

2

277

Mean Difference (IV, Fixed, 95% CI)

‐0.18 [‐0.25, ‐0.11]

9 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

3

409

Mean Difference (IV, Fixed, 95% CI)

‐1.37 [‐1.79, ‐0.96]

9.1 Children

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Adults

3

409

Mean Difference (IV, Fixed, 95% CI)

‐1.37 [‐1.79, ‐0.96]

10 Methacholine BHR (log base 2 PC20 FEV1 mg/ml) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

10.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11 Physician‐rated efficacy: effective or very effective (No. of patients) Show forest plot

2

311

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.62 [6.18, 14.99]

11.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 Adults

2

311

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.62 [6.18, 14.99]

12 Morning plasma cortisol (mcg/dL) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

12.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

13 Change in morning plasma cortisol compared to baseline (mcg/dL) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

13.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

13.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

14 8 hour area under curve (AUC) plasma cortisol during 6 hour 250 mcg co‐syntropin infusion (mcg hour/dL) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

14.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

14.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

15 Peak plasma cortisol during during 6 hour 250 mcg co‐syntropin infusion (mcg/dL) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

15.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

15.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

16 Withdrawal due to clinical asthma exacerbation (No. of patients) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

16.1 Children

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

16.2 Adults

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

17 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

5

671

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.11 [0.08, 0.15]

17.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

17.2 Adults

5

671

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.11 [0.08, 0.15]

18 Sore throat or pharyngitis (No. of patients) Show forest plot

4

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.95 [1.83, 13.43]

18.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

18.2 Adults

4

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.95 [1.83, 13.43]

19 Hoarseness or dysphonia (No. of patients) Show forest plot

6

770

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.99 [3.54, 18.01]

19.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

19.2 Adults

6

770

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.99 [3.54, 18.01]

20 Oral Candidiasis (No. of patients) Show forest plot

6

770

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.77 [2.32, 9.80]

20.1 Children

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

20.2 Adults

6

770

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.77 [2.32, 9.80]

21 HRQOL: AQLQ Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

21.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

21.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

22 Log PD20 mg Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

22.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

22.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

23 FVC (absolute values ‐ Litres) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

23.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

23.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

24 Withdrawals (any reason) Show forest plot

2

130

Odds Ratio (M‐H, Fixed, 95% CI)

1.91 [0.91, 4.00]

24.1 Children

0

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

24.2 Adults

2

130

Odds Ratio (M‐H, Fixed, 95% CI)

1.91 [0.91, 4.00]
Figuras y tablas -
Comparison 13. FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all ages)
Ir a la tabla de la revisión
Comparison 14. FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 FEV1 (litres) Show forest plot

3

73

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.22, 0.48]

1.1 1‐4 weeks

2

42

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.54, 0.30]

1.2 1‐5 months

1

31

Mean Difference (IV, Fixed, 95% CI)

0.66 [0.04, 1.28]

1.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Change in FEV1 compared to baseline (litres) Show forest plot

3

414

Mean Difference (IV, Fixed, 95% CI)

0.53 [0.43, 0.63]

2.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 1‐5 months

3

414

Mean Difference (IV, Fixed, 95% CI)

0.53 [0.43, 0.63]

2.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5 Change in morning PEFR compared to baseline (L/min) Show forest plot

4

624

Mean Difference (IV, Fixed, 95% CI)

46.85 [39.64, 54.07]

5.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 1‐5 months

4

624

Mean Difference (IV, Fixed, 95% CI)

46.85 [39.64, 54.07]

5.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Change in evening PEFR compared to baseline (L/min) Show forest plot

2

278

Mean Difference (IV, Fixed, 95% CI)

41.12 [31.36, 50.87]

6.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 1‐5 months

2

278

Mean Difference (IV, Fixed, 95% CI)

41.12 [31.36, 50.87]

6.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Change in daily asthma symptom score compared to baseline Show forest plot

3

412

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.65 [‐0.85, ‐0.46]

7.1 1‐4 weeks

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 1‐5 months

3

412

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.65 [‐0.85, ‐0.46]

7.3 6 months or longer

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Change in number of night‐time awakening per week compared to baseline score Show forest plot

2

277

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐0.85, ‐0.36]

8.1 1‐4 weeks

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 1‐5 months

2

277

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐0.85, ‐0.36]

8.3 6 months or longer

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

3

409

Mean Difference (IV, Fixed, 95% CI)

‐1.37 [‐1.79, ‐0.96]

9.1 1‐4 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 1‐5 months

3

409

Mean Difference (IV, Fixed, 95% CI)

‐1.37 [‐1.79, ‐0.96]

9.3 6 months or longer

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11 Physician‐rated efficacy: effective or very effective (No. of patients) Show forest plot

2

311

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.62 [6.18, 14.99]

11.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 1‐5 months

2

311

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.62 [6.18, 14.99]

11.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

17 Withdrawal due to lack of treatment efficacy (No.of patients) Show forest plot

4

566

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.11 [0.07, 0.15]

17.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

17.2 1‐5 months

4

566

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.11 [0.07, 0.15]

17.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

18 Sore throat or pharyngitis (No. of patients) Show forest plot

3

419

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.65 [1.70, 18.79]

18.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

18.2 1‐5 months

3

419

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.65 [1.70, 18.79]

18.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

19 Hoarseness or dysphonia (No. of patients) Show forest plot

5

665

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.92 [3.25, 19.30]

19.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

19.2 1‐5 months

5

665

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.92 [3.25, 19.30]

19.3 6 months or longer

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

20 Oral Candidiasis (No. of patients) Show forest plot

6

770

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.77 [2.32, 9.80]

20.1 1‐4 weeks

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

20.2 1‐5 months

5

665

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.99 [1.76, 9.03]

20.3 6 months or longer

1

105

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.89 [1.93, 40.93]
Figuras y tablas -
Comparison 14. FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all treatment durations)
Ir a la tabla de la revisión
Comparison 15. FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 FEV1 (litres) Show forest plot

3

73

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.22, 0.48]

1.1 1‐4 weeks

2

42

Mean Difference (IV, Fixed, 95% CI)

‐0.12 [‐0.54, 0.30]

1.3 MDI

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.4 DPI

1

31

Mean Difference (IV, Fixed, 95% CI)

0.66 [0.04, 1.28]

2 Change in FEV1 compared to baseline (litres) Show forest plot

3

414

Mean Difference (IV, Fixed, 95% CI)

0.53 [0.43, 0.63]

2.1 MDI

1

159

Mean Difference (IV, Fixed, 95% CI)

0.52 [0.38, 0.66]

2.2 DPI

2

255

Mean Difference (IV, Fixed, 95% CI)

0.53 [0.40, 0.67]

5 Change in morning PEFR compared to baseline (L/min) Show forest plot

3

422

Mean Difference (IV, Fixed, 95% CI)

49.38 [40.83, 57.93]

5.1 MDI

1

169

Mean Difference (IV, Fixed, 95% CI)

58.0 [43.82, 72.18]

5.2 DPI

2

253

Mean Difference (IV, Fixed, 95% CI)

44.46 [33.75, 55.17]

6 Change in evening PEFR compared to baseline (L/min) Show forest plot

2

278

Mean Difference (IV, Fixed, 95% CI)

41.12 [31.36, 50.87]

6.1 MDI

1

159

Mean Difference (IV, Fixed, 95% CI)

48.0 [35.35, 60.65]

6.2 DPI

1

119

Mean Difference (IV, Fixed, 95% CI)

31.0 [15.67, 46.33]

7 Change in daily asthma symptom score compared to baseline Show forest plot

3

412

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.65 [‐0.85, ‐0.46]

7.1 MDI

1

159

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.76 [‐1.08, ‐0.44]

7.2 DPI

2

253

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.59 [‐0.84, ‐0.34]

8 Change in night‐time awakening per week compared to baseline Show forest plot

2

277

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐0.85, ‐0.36]

8.1 MDI

1

159

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.73 [‐1.06, ‐0.41]

8.2 DPI

1

118

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.43 [‐0.80, ‐0.07]

9 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

3

409

Mean Difference (IV, Fixed, 95% CI)

‐1.37 [‐1.79, ‐0.96]

9.1 MDI

1

159

Mean Difference (IV, Fixed, 95% CI)

‐0.96 [‐1.48, ‐0.44]

9.2 DPI

2

250

Mean Difference (IV, Fixed, 95% CI)

‐2.06 [‐2.74, ‐1.39]

11 Physician‐rated efficacy: effective or very effective (No. of patients) Show forest plot

2

311

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.62 [6.18, 14.99]

11.1 MDI

2

311

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.62 [6.18, 14.99]

11.2 DPI

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

17 Withdrawal due to lack of treatment efficacy (No. of patients) Show forest plot

4

566

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.11 [0.07, 0.15]

17.1 MDI

2

311

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.08 [0.05, 0.13]

17.2 DPI

2

255

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.16 [0.09, 0.28]

18 Sore throat or pharyngitis (No. of patients) Show forest plot

3

419

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.65 [1.70, 18.79]

18.1 MDI

1

152

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.29 [0.45, 117.74]

18.2 DPI

2

267

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.33 [1.41, 20.20]

19 Hoarseness or dysphonia (No. of patients) Show forest plot

5

665

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.92 [3.25, 19.30]

19.1 MDI

3

398

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.06 [2.87, 22.61]

19.2 DPI

2

267

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.53 [1.29, 43.98]

20 Oral Candidiasis (No. of patients) Show forest plot

6

770

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.77 [2.32, 9.80]

20.1 MDI

4

503

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.28 [3.14, 21.84]

20.2 DPI

2

267

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.41 [0.82, 7.08]
Figuras y tablas -
Comparison 15. FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all delivery devices)
Ir a la tabla de la revisión
Comparison 16. FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 FEV1 (litres) Show forest plot

3

73

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.22, 0.48]

1.1 Mild

3

73

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.22, 0.48]

1.2 Mild to moderate

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.3 Moderate

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Change in FEV1 compared to baseline (litres) Show forest plot

3

414

Mean Difference (IV, Fixed, 95% CI)

0.53 [0.43, 0.63]

2.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Mild to moderate

2

281

Mean Difference (IV, Fixed, 95% CI)

0.50 [0.39, 0.61]

2.3 Moderate

1

133

Mean Difference (IV, Fixed, 95% CI)

0.61 [0.41, 0.81]

5 Change in morning PEFR compared to baseline (L/min) Show forest plot

3

422

Mean Difference (IV, Fixed, 95% CI)

49.38 [40.83, 57.93]

5.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Mild to moderate

2

289

Mean Difference (IV, Fixed, 95% CI)

59.25 [48.43, 70.07]

5.3 Moderate

1

133

Mean Difference (IV, Fixed, 95% CI)

33.0 [19.06, 46.94]

6 Change in evening PEFR compared to baseline (L/min) Show forest plot

2

278

Mean Difference (IV, Fixed, 95% CI)

41.12 [31.36, 50.87]

6.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Mild to moderate

2

278

Mean Difference (IV, Fixed, 95% CI)

41.12 [31.36, 50.87]

6.3 Moderate

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Change in daily asthma symptom score compared to baseline Show forest plot

3

412

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.65 [‐0.85, ‐0.46]

7.1 Mild

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 Mild to moderate

2

279

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.70 [‐0.94, ‐0.46]

7.3 Moderate

1

133

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.57 [‐0.91, ‐0.22]

8 Change in night‐time wakening score Show forest plot

2

277

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐0.85, ‐0.36]

8.1 Mild

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 Mild to moderate

2

277

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐0.85, ‐0.36]

8.3 Moderate

0

0

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Change in daily use of beta2 agonist compared to baseline (puffs/d) Show forest plot

3

409

Mean Difference (IV, Fixed, 95% CI)

‐1.37 [‐1.79, ‐0.96]

9.1 Mild

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Mild to moderate

2

276

Mean Difference (IV, Fixed, 95% CI)

‐1.28 [‐1.74, ‐0.83]

9.3 Moderate

1

133

Mean Difference (IV, Fixed, 95% CI)

‐1.8 [‐2.78, ‐0.82]

11 Physician‐rated efficacy: effective or very effective (No. of patients) Show forest plot

2

311

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.62 [6.18, 14.99]

11.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 Mild to moderate

1

159

Peto Odds Ratio (Peto, Fixed, 95% CI)

14.53 [7.82, 27.01]

11.3 Moderate

1

152

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.25 [3.32, 11.79]

17 Withdrawal due to lack of treatment efficacy (No.of patients) Show forest plot

4

566

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.11 [0.07, 0.15]

17.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

17.2 Mild to moderate

2

281

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.10 [0.06, 0.16]

17.3 Moderate

2

285

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.11 [0.07, 0.19]

18 Sore throat or pharyngitis (No. of patients) Show forest plot

3

419

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.65 [1.70, 18.79]

18.1 Mild

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

18.2 Mild to moderate

1

134

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.92 [1.08, 22.44]

18.3 Moderate

2

285

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.13 [1.00, 51.03]

19 Hoarseness or dysphonia (No. of patients) Show forest plot

5

665

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.92 [3.25, 19.30]

19.1 Mild

1

82

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.77 [0.79, 76.88]

19.2 Mild to moderate

2

298

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.38 [2.50, 28.02]

19.3 Moderate

2

285

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.23 [1.44, 36.28]

20 Oral Candidiasis (No. of patients) Show forest plot

6

770

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.77 [2.32, 9.80]

20.1 Mild

2

187

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.53 [2.39, 30.39]

20.2 Mild to moderate

2

298

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.62 [1.03, 12.74]

20.3 Moderate

2

285

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.61 [1.06, 12.23]
Figuras y tablas -
Comparison 16. FP versus placebo: Parallel group studies, no oral steroids: 1000‐1500 mcg/d (all degrees asthma severity)
Ir a la tabla de la revisión
Comparison 17. FP versus placebo: Parallel group studies, no oral steroids: 2000 mcg/d (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 PD20 ‐ change from baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

1.1 Children

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Adults

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 17. FP versus placebo: Parallel group studies, no oral steroids: 2000 mcg/d (all ages)
Ir a la tabla de la revisión
Comparison 18. FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 FEV1 (% predicted ‐ absolute values) Show forest plot

1

% (Fixed, 95% CI)

Totals not selected

1.1 Children

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Adults

1

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

2 PEF (% predicted ‐ absolute values) Show forest plot

1

% (Fixed, 95% CI)

Totals not selected

2.1 Children

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Adults

1

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Quality of life (absolute scores ‐ AQLQ) Show forest plot

1

QoL (Fixed, 95% CI)

Totals not selected

3.1 Children

0

QoL (Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Adults

1

QoL (Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Symptoms Show forest plot

1

Symptom score (Fixed, 95% CI)

Totals not selected

4.1 Children

0

Symptom score (Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Adults

1

Symptom score (Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Rescue medication usage (unclear time frame ‐ absolute values) Show forest plot

1

Puffs (Fixed, 95% CI)

Totals not selected

6.1 Children

0

Puffs (Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Adults

1

Puffs (Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 18. FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages)
Ir a la tabla de la revisión
Comparison 19. FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 FEV1 Show forest plot

1

Litres (Fixed, 95% CI)

Totals not selected

1.1 Children

0

Litres (Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Adults

1

Litres (Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Throat irritation Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2.1 Children

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Adults

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Upper respiratory tract infections Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

3.1 Children

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Adults

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Lower respiratory tract infection Show forest plot

1

Odds Ratio (M‐H, Fixed, 95% CI)

Totals not selected

4.1 Children

0

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Adults

1

Odds Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 19. FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages)
Ir a la tabla de la revisión
Comparison 20. FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 FEV1 (absolute values) Show forest plot

1

Litres (Fixed, 95% CI)

Totals not selected

1.1 Children

0

Litres (Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Adults

1

Litres (Fixed, 95% CI)

0.0 [0.0, 0.0]

2 PC 20 Show forest plot

2

70

Doses (n) (Fixed, 95% CI)

2.45 [1.63, 3.27]

2.1 Children

0

0

Doses (n) (Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Adults

2

70

Doses (n) (Fixed, 95% CI)

2.45 [1.63, 3.27]

3 Cortisol suppression Show forest plot

1

% (Fixed, 95% CI)

Totals not selected

3.1 Children

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Adults

1

% (Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 20. FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages)
Ir a la tabla de la revisión
Comparison 21. FP versus placebo: Crossover studies, no oral steroids: 1000mcg/d (all ages)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Cortisol suppression Show forest plot

1

% (Fixed, 95% CI)

Totals not selected

1.1 Children

0

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Adults

1

% (Fixed, 95% CI)

0.0 [0.0, 0.0]

2 PC 20 Show forest plot

2

100

Doses (n) (Fixed, 95% CI)

2.82 [2.13, 3.51]

2.1 Children

0

0

Doses (n) (Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Adults

2

100

Doses (n) (Fixed, 95% CI)

2.82 [2.13, 3.51]
Figuras y tablas -
Comparison 21. FP versus placebo: Crossover studies, no oral steroids: 1000mcg/d (all ages)
Ir a la tabla de la revisión
Comparison 22. FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of patients able to discontinue OCS completely Show forest plot

2

139

Peto Odds Ratio (Peto, Fixed, 95% CI)

14.07 [7.17, 27.57]

2 Change in daily dose of oral prednisolone compared to baseline (mg) Show forest plot

2

139

Mean Difference (IV, Fixed, 95% CI)

‐7.59 [‐9.92, ‐5.25]

3 Change in FEV1 compared to baseline (litres) Show forest plot

2

139

Mean Difference (IV, Fixed, 95% CI)

0.26 [0.09, 0.43]

4 Change in morning PEFR compared to baseline (L/min) Show forest plot

2

139

Mean Difference (IV, Fixed, 95% CI)

50.85 [30.96, 70.73]

5 Change in evening PEFR compared to baseline (L/min) Show forest plot

2

139

Mean Difference (IV, Fixed, 95% CI)

26.52 [6.40, 46.65]

6 Change in daily asthma symptom score compared to baseline Show forest plot

2

139

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.76 [‐1.10, ‐0.41]

7 Change in daily use of rescue beta2 agonist compared to baseline (puffs/d) Show forest plot

2

139

Mean Difference (IV, Fixed, 95% CI)

‐3.60 [‐5.04, ‐2.16]

8 Asthma Quality of Life Questionnaire: change in overall score compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

9 Asthma Quality of Life Questionnaire: change in activity limitation domain compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

10 Asthma Quality of Life Questionnaire: change in asthma symptoms domain compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

11 Asthma Quality of Life Questionnaire: change in emotional function domain compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

12 Asthma Quality of Life Questionnaire: change in enviromental exposure domain compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

14 Sore throat (No. of patients) Show forest plot

2

139

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.42 [0.33, 17.64]

15 Hoarseness or dysphonia (No. of patients) Show forest plot

2

139

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.19 [1.41, 36.63]

17 Oral Candidiasis (No. of patients) Show forest plot

2

139

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.71 [1.98, 16.47]
Figuras y tablas -
Comparison 22. FP versus placebo: Parallel group studies, oral steroid dependent: 1000‐1500 mcg/d
Ir a la tabla de la revisión
Comparison 23. FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of patients able to discontinue OCS completely Show forest plot

2

134

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.04 [0.02, 0.08]

2 Change in daily dose of oral prednisolone compared to baseline (mg) Show forest plot

2

134

Mean Difference (IV, Fixed, 95% CI)

‐9.72 [‐12.10, ‐7.35]

3 Change in FEV1 compared to baseline (litres) Show forest plot

2

134

Mean Difference (IV, Fixed, 95% CI)

0.58 [0.40, 0.76]

4 Change in morning PEFR compared to baseline (L/min) Show forest plot

2

134

Mean Difference (IV, Fixed, 95% CI)

94.35 [72.51, 116.19]

5 Change in evening PEFR compared to baseline (L/min) Show forest plot

2

134

Mean Difference (IV, Fixed, 95% CI)

66.14 [43.04, 89.24]

6 Change in daily asthma symptom score compared to baseline Show forest plot

2

134

Std. Mean Difference (IV, Fixed, 95% CI)

‐1.03 [‐1.39, ‐0.67]

7 Change in daily use of rescue beta2 agonist compared to baseline (puffs/d) Show forest plot

2

134

Mean Difference (IV, Fixed, 95% CI)

‐4.63 [‐6.10, ‐3.15]

8 Asthma Quality of Life Questionnaire: change in overall score compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

9 Asthma Quality of Life Questionnaire: change in activity limitation domain compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

10 Asthma Quality of Life Questionnaire: change in asthma symptoms domain compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

11 Asthma Quality of Life Questionnaire: change in emotional function domain compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

12 Asthma Quality of Life Questionnaire: change in enviromental exposure domain compared to baseline Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

14 Sore throat (No. of patients) Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

15 Hoarseness or dysphonia (No. of patients) Show forest plot

2

134

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.63 [1.50, 38.92]

16 Oral Candidiasis (No. of patients) Show forest plot

2

134

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.62 [1.70, 12.51]
Figuras y tablas -
Comparison 23. FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d
Ir a la tabla de la revisión